Single-Cell Landscape of the Colon Cancer Microenvironment: Cellular Dynamics, Genomic Instability, and Immune Dysregulation
This report delineates the single-cell landscape of human colon tissue, comparing normal and tumor conditions. Key findings reveal that tumor-origin Intestinal Epithelial cells exhibit hallmarks of malignancy, including aneuploidy and significant upregulation of cell cycle and oncogenic pathways. The tumor microenvironment is profoundly reshaped, characterized by an influx of pro-tumorigenic fibroblasts and a complex immune infiltrate marked by expanded immunosuppressive T cell subsets (Tregs, Th17, Th22) and M2-like macrophages. Altered cell-cell interactions, including immune checkpoints and adhesion molecules, further contribute to immune evasion and tumor progression.
Contents
- Dataset overview
- UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy Status
- Marker Gene Expression and Cell Type Annotation Validation on UMAP
- Celltype_subset Marker Expression Dot Plot Analysis
- Analysis of Copy Number Variations in Intestinal Epithelial and Unassigned Cells
- CNV-Based UMAP Embedding and Cell Annotation Analysis in Colon Tissue
- Colon Tissue Minor Cell Type Population Analysis
- T Cell Subset Population Analysis in Colon Normal vs. Tumor Conditions
- Macrophage Subset Population Analysis in Colon Normal vs. Tumor Tissues
- T Cell Subset Population Shifts in Colon Cancer
- Differential Macrophage Subset Proportions in Colon Tumor Microenvironment
- Ploidy Analysis of Tumor-Origin and Unassigned Cells in Normal and Tumor Colon Samples
- Normal Colon Cell-Cell Interaction Patterns Focused on Epithelial and T Cells
- Tumor 미세환경 내 Cell-Cell 상호작용 분석: 주요 Ligand-Receptor 쌍 및 생물학적 함의
- Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Related Genes in Colon Tissue
- Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
- Intestinal Epithelial Cell Condition-Specific Surfaceome Markers
- Cell-Type Specific Surfaceome Markers for Macrophage Subtypes in Human Colon
- Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
- Condition-Specific Surfaceome Markers in CD4+ T cells
- Intestinal Epithelial Cell Cycle Deregulation in Colon Tumorigenesis
- Intestinal Epithelial Cell Gene Ontology (GSA) Analysis: Ploidy and Tumor-Associated Pathway Shifts
- Major Cell Type GSEA for Colon Tissue: Insights into Tumor Microenvironment Pathways
- Discussion
- Query List
0. Dataset overview
Dataset Summary
- Data Type: Single-cell RNA-seq data, processed by SCODA.
- Dimensions: Contains 48,033 cells and 20,683 genes.
- Species: Human
- Tissue: Colon
- Conditions: Normal, Tumor
- Observed Columns (Cell Metadata): Includes information such as samples, Condition, Location, MSI_Status, various cell type annotations (celltype_major, celltype_minor, celltype_subset), ploidy inference (ploidy_dec), and more.
- Variable Columns (Gene Metadata): Contains variable_genes, chromosome, spot_no, and cytogenetic_band.
- Tumor Origin Celltype: Intestinal Epithelial cell
- Ploidy Status: Cells are classified as Aneuploid or Diploid.
Precomputed Results
- Cell-Cell Interaction (CCI): Results are available at both condition-level (uns['CCI']) and sample-level (uns['CCI_sample']).
- Differential Expression Genes (DEG): Results for each celltype_minor, comparing one condition versus the rest (uns['DEG']).
- Gene Set Enrichment Analysis (GSEA): Results for each celltype_minor, comparing one condition versus the rest (uns['GSEA']).
- Gene Ontology (GO/GSA): Upregulated GO results for each celltype_minor, comparing one condition versus the rest (uns['GSA_up']).
- Copy Number Variation (CNV): Estimates are stored in obsm['X_cnv'].
Available Cell Types for Specific Analyses
- For DEG, GSEA, and GSA/GO analyses, target cell types can be selected from: B cell, Fibroblast, ILC, Intestinal Epithelial cell, Plasma cell, T cell CD4+, T cell CD8+.
1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy Status
[Analysis Visualization Results]...
Analysis Overview
This analysis presents UMAP (Uniform Manifold Approximation and Projection) plots, which are commonly used for dimensionality reduction and visualization of single-cell RNA-seq data. These plots project high-dimensional gene expression data into a 2D space, allowing for the visual inspection of cellular heterogeneity and relationships. The UMAPs are colored by various metadata features: condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. This comprehensive visualization helps in understanding the overall structure of the dataset, assessing the quality of cell type annotations, evaluating potential batch effects, and identifying disease-specific or cell-specific patterns.
Visual Summary
Condition
The UMAP colored by condition shows a clear separation, with a large, dense cluster prominently occupied by 'tumor' cells (dark blue) and other regions predominantly by 'normal' cells (maroon). However, there is also significant mixing of 'normal' and 'tumor' cells in several areas, indicating shared cell types or similar cellular states across both conditions, or immune/stromal infiltration into the tumor microenvironment.
Sample
The sample UMAP displays a remarkable intermixing of cells from various samples across the major clusters. This suggests that the data integration process was successful in minimizing strong sample-specific batch effects, allowing for robust comparisons across samples. While some small peripheral clusters might show slight enrichment for certain samples, the overall embedding structure is not dominated by individual sample identities.
Cell Type (Major, Minor, Subset)
The UMAPs colored by celltype_major, celltype_minor, and celltype_subset consistently demonstrate well-defined and distinct clusters for the annotated cell types at all hierarchical levels.
- celltype_major: Major cell lineages such as T cells (teal), B cells (maroon), Intestinal Epithelial cells (orange), and Stromal cells (light blue) form largely separate and coherent clusters. This indicates robust identification of primary cell populations.
- celltype_minor: Further resolution shows expected sub-clustering within major groups, for example, T cell CD4+ (light blue) and T cell CD8+ (dark blue) clearly separating within the T cell major cluster. Plasma cells (light green) are distinct, often adjacent to B cells. Intestinal Epithelial cells (orange) maintain a large, distinct cluster.
- celltype_subset: At the highest resolution, highly specific cell populations like various T cell subsets (e.g., T_Naive, Th17, Treg), B cell subsets (e.g., Memory B cell, Plasma cell), and diverse Intestinal Epithelial cell types (e.g., Enterocyte, Goblet cell, Paneth cell) are all well-resolved and form distinct clusters. This detailed separation confirms the quality and specificity of the cell type annotations. A small proportion of "unassigned" cells (purple) are scattered but do not form a prominent cluster, suggesting most cells are well-classified.
Ploidy Dec
The ploidy_dec UMAP reveals a striking pattern: 'Aneuploid' cells (maroon) are highly concentrated in a specific region of the UMAP space, largely overlapping with the main Intestinal Epithelial cell cluster. In contrast, 'Diploid' cells (yellow) are widely distributed across the entire UMAP, encompassing most other cell types and regions. Very few 'Unclear' cells (dark blue) are observed.
Biological Interpretation
The comprehensive UMAP analysis provides several key biological insights into the colon tissue dataset:
- Distinct Cellular Landscapes in Normal vs. Tumor Conditions: The condition UMAP highlights that while there are shared cellular components between normal and tumor colon tissue, there are also significant shifts in cell populations or states specific to the tumor microenvironment. The large 'tumor'-enriched cluster suggests the presence of tumor-specific malignant cells and/or immune/stromal cells that are heavily reprogrammed in the tumor context.
- Robust Cell Type Annotation: The excellent separation of major, minor, and subset cell types into distinct clusters confirms the high quality of the cell type annotations. This provides a strong foundation for downstream differential gene expression, pathway analysis, and cell-cell interaction studies, ensuring that comparisons are made between genuinely distinct cell populations. The identification of various immune, stromal, and epithelial cell subsets aligns with the known cellular complexity of the colon and its tumor microenvironment.
- Identification of Malignant Cells by Ploidy: The most impactful finding from these UMAPs is the strong co-localization of 'Aneuploid' cells with the Intestinal Epithelial cell cluster, especially within the 'tumor' condition. Given that "Intestinal Epithelial cell" is designated as the "Tumor origin celltype" and aneuploidy is a hallmark of cancer, this observation provides strong evidence for the successful identification and clustering of the malignant epithelial cells [1]. These aneuploid epithelial cells likely represent the cancerous cell population in the colon tumor samples, distinguishing them from normal epithelial cells or other stromal and immune cells, which are predominantly diploid. This distinction is critical for studying tumor-intrinsic biology and identifying potential therapeutic targets within the malignant cells.
Annotation Notes
The consistency and distinctness of cell type clusters across major, minor, and subset levels suggest a robust annotation pipeline. The successful integration of samples, as evidenced by the intermixing in the sample UMAP, indicates that biological variations rather than technical artifacts drive the observed cell clustering. The clear pattern of aneuploidy supporting the identification of tumor epithelial cells further validates the biological relevance of the annotations.
---
References:
[1] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646–674. PubMed Search: "Hallmarks of Cancer"
2. Marker Gene Expression and Cell Type Annotation Validation on UMAP
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the expression of a panel of known marker genes on a UMAP projection, alongside the celltype_minor annotation. The primary goal is to validate the consistency and specificity of the minor cell type annotations within the single-cell RNA-seq dataset by examining the spatial distribution of these key gene expressions. This helps confirm the identity of distinct cell populations.
Visual Summary
The UMAP plots clearly display cell clusters based on their transcriptional profiles. The celltype_minor plot serves as a reference, showing discrete clusters corresponding to annotated cell types such as T cell CD4+, T cell CD8+, B cell, Plasma cell, Intestinal Epithelial cell, Macrophage, Dendritic cell, Fibroblast, and Endothelial cell.
Individual gene expression plots reveal distinct patterns:
- T Cell Markers (CD3D, CD4, CD8A): CD3D, a pan T cell marker, shows broad expression across the T cell clusters (T CD4+ and T CD8+). CD4 expression is highly concentrated in the "T CD4+" cluster, while CD8A expression is specifically localized to the "T CD8+" cluster, demonstrating clear distinction and accurate annotation of these two T cell subsets.
- B Cell and Plasma Cell Markers (CD79A, MS4A1, MZB1): CD79A, a pan B cell and plasma cell marker, is expressed strongly in both B cell and Plasma cell clusters. MS4A1 (CD20) is robustly expressed in the "B cell" cluster, as expected, but shows reduced expression in the "Plasma" cell cluster. MZB1, a specific plasma cell marker, is predominantly expressed within the "Plasma" cell cluster.
- Myeloid Cell Markers (CD14, LYZ): CD14 and LYZ both exhibit high expression within the "Macrophage" and "DC" (Dendritic cell) clusters, consistent with their roles in myeloid lineage cells.
- Stromal Cell Markers (FBLN1, NOTCH3, CD34): FBLN1 is specifically expressed in the "Fibroblast" cluster. CD34 shows clear expression in the "Endothelial cell" cluster. NOTCH3 shows more diffuse but noticeable expression patterns, with some signal observed in regions corresponding to Endothelial cells and potentially Smooth muscle cells.
- Epithelial Cell Markers (EPCAM, MUC1): Both EPCAM and MUC1 are highly and specifically expressed in the "Intestinal Epithelial cell" cluster, confirming the identity of this major cell population.
Biological Interpretation
The observed gene expression patterns on the UMAP are highly consistent with the established roles of these genes as markers for specific cell types. This provides strong validation for the celltype_minor annotations generated from the single-cell RNA-seq data.
- Immune Cell Lineages: The clear segregation of T cells (CD3D, CD4, CD8A), B cells (CD79A, MS4A1), and Plasma cells (MZB1) into distinct, marker-defined clusters confirms the accurate identification of these major adaptive immune populations. The differential expression of CD4 and CD8A within the T cell compartment further validates the subtyping of helper and cytotoxic T lymphocytes https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD4, https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD8A. The co-expression of CD14 and LYZ in Macrophage and DC clusters correctly identifies myeloid immune populations https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD14.
- Structural and Stromal Cells: The robust expression of EPCAM and MUC1 exclusively within the "Intestinal Epithelial cell" cluster confirms the integrity of the epithelial compartment, which is crucial given the tissue origin (Colon) and the designation of Intestinal Epithelial cells as the "Tumor origin celltype" in the data context https://www.genecards.org/cgi-bin/carddisp.pl?gene=EPCAM. The specific expression of FBLN1 in fibroblasts and CD34 in endothelial cells also validates the identification of key stromal components within the tissue microenvironment.
- Annotation Quality: The precise colocalization of high marker gene expression with their expected celltype_minor labels indicates a high quality of cell type annotation and clustering. This foundational validation step is critical for downstream analyses, such as differential gene expression (DEG), gene set enrichment analysis (GSEA), or cell-cell interaction (CCI) studies, ensuring that these analyses are performed on accurately defined cell populations.
Annotation Notes
The strong agreement between the canonical marker gene expression and the celltype_minor assignments confirms that the clustering and annotation processes have successfully captured biologically distinct cell populations present in the colon tissue. This robust cell type identification forms a reliable basis for further in-depth biological investigations related to conditions (normal vs. tumor) and other metadata features within the dataset.
3. Celltype_subset Marker Expression Dot Plot Analysis
[Analysis Visualization Results]...
Analysis Overview
This dot plot visualizes the expression of marker genes across various celltype_subset populations identified in the single-cell RNA-seq data from human colon tissue. Each row represents a celltype_subset, and each column represents a marker gene. The size of the dot indicates the fraction of cells within that cell type expressing the gene, while the color intensity (from light red to dark red) represents the mean expression level of the gene within that cell type. This analysis serves as a crucial step for validating the quality and specificity of the celltype_subset annotations based on known biological markers.
Visual Summary
The dot plot displays a clear diagonal pattern, indicating that distinct sets of genes are preferentially expressed in specific celltype_subset groups. This "block-like" structure on the diagonal is a strong visual indicator of well-defined cell populations with unique transcriptional signatures.
- Specificity and Expression: Most celltype_subset populations exhibit strong, highly specific marker gene expression (large, dark red dots) with minimal off-target expression in other cell types, suggesting robust annotation.
- Fraction of Cells Expressing: For many markers, a high fraction of cells within their respective celltype_subset express the gene (large dot size), reinforcing their role as defining markers.
- Shared Markers: While most markers are specific, some genes show expression across related cell types or even across broader categories, for example, certain B cell markers are shared among B cell subsets, and some pan-immune or pan-epithelial markers might appear. However, the overall pattern emphasizes distinct markers for each subset.
- Clarity of Annotation: The distinct blocks for various T cell subsets, B cell subsets, epithelial cells, and myeloid cells suggest good separation and identification of these groups.
Biological Interpretation
The marker expression patterns largely support the assigned celltype_subset annotations within the human colon scRNA-seq dataset.
Immune Cell Subsets
B cell subsets:
- B cell (Breg), B cell (Follicular), B cell (MZ), B cell (Memory): These subsets show shared expression of pan-B cell markers like *CD24* and *CD22* GeneCards: CD24, GeneCards: CD22. Distinct markers help differentiate them, for example, *POU2AF1* (also known as BOB1 or OBF1) and *CD86* are observed across several B cell subsets, consistent with B cell activation and antigen presentation functions GeneCards: POU2AF1.
- Plasma cell: Characterized by high expression of genes like *XBP1*, *MZB1*, *JCHAIN*, *PRDM1* (BLIMP1), and *SDC1* (CD138) GeneCards: SDC1, which are critical for immunoglobulin production and secretion, firmly validating this annotation.
T cell subsets:
- T cell (Cytotoxic), T cell (Naive), T cell (Tfh), T cell (Th1), T cell (Th17), T cell (Th2), T cell (Th22), T cell (Treg): These groups show expected lineage-defining markers.
- T cell (Cytotoxic): High expression of *GZMB*, *GZMK*, *CD8A*, *CD8B* strongly supports cytotoxic T lymphocyte identity GeneCards: GZMB, GeneCards: CD8A.
- T cell (Naive): Markers such as *SELL* (CD62L) and *LEF1* are typically found in naive T cells GeneCards: SELL.
- T cell (Tfh): Expression of *CD40LG* (CD154) and *PDCD1* (PD-1) is consistent with T follicular helper cell function in B cell collaboration GeneCards: PDCD1.
- T cell (Th1): Marked by *STAT1* and *IFNGR1* GeneCards: STAT1.
- T cell (Th17): Characterized by *RORC* and *IL27RA* GeneCards: RORC.
- T cell (Treg): The expression of *FOXP3*, *CTLA4*, and *CD5* are classic markers for regulatory T cells GeneCards: FOXP3.
- The distinct expression patterns among T helper subsets (Th1, Th2, Th17, Th22) and Tregs reflect their specialized roles in immunity.
Myeloid cells:
- Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), Macrophage (M2D): These subsets show differential expression of macrophage-associated genes. For instance, *MSR1* is a scavenger receptor often expressed on macrophages. The presence of distinct macrophage polarization markers supports the granular sub-classification GeneCards: MSR1.
- Dendritic cell (Plasmacytoid), DC (Inflammatory), DC (Classical): While not all markers are shown explicitly in the provided image, the presence of distinct macrophage and DC populations aligns with the expected immune landscape of the colon.
- Mast cell: Characterized by markers such as *KIT*, *TPSAB1*, and *SRGN* GeneCards: KIT.
- NK cell: Markers include *KLRF1* (NKG2D) and *KLRD1* (CD94) GeneCards: KLRF1.
- ILC subsets (ILC1, ILC2, ILC3 (NCR-), ILC3 (NCR+), ILCreg): Show specific markers such as *EHF* and *FCGR3A*.
Epithelial and Stromal Cells
Intestinal Epithelial cell subsets:
- Enterocyte: Strong expression of *FABP1*, *CDH17*, and *KRT20* GeneCards: FABP1.
- Goblet cell: Marked by high expression of mucin genes like *MUC2* GeneCards: MUC2 and *TFF3*.
- Paneth cell: Identified by genes such as *DEF5*, *LYZ* (lysozyme), and *SPINK4* GeneCards: LYZ.
- Tuft cell: Marked by *PTGS1*, *AVIL*, and *TRPM5* GeneCards: TRPM5.
- Crypt cell: Marked by *ASCL2* and *LGR5*, which are stem cell markers found in intestinal crypts GeneCards: LGR5.
- Microfold cell (M cell): Shows distinct expression of *GPX2*.
Stromal cell subsets:
- Fibroblast: Exhibits expression of various collagen genes (*COL1A1, COL1A2, COL3A1, COL6A2*) and *DCN* (decorin) and *LUM* (lumican) GeneCards: COL1A1, GeneCards: DCN.
- Smooth muscle cell: Expresses *ACTA2* (alpha-smooth muscle actin), *CNN1*, and *MYH11* GeneCards: ACTA2.
Endothelial cell subsets
- Endothelial cell, Endothelial tip cell, Lymphatic Endothelial cell: These subsets are generally well-resolved, with typical endothelial markers such as *CD36* and *ESM1*.
Annotation Notes
The dot plot strongly validates the celltype_subset annotations for most populations in this colon single-cell RNA-seq dataset.
- The clear and specific expression of known marker genes for almost all celltype_subset groups indicates high confidence in the cell type assignments.
- The distinct diagonal blocks for various immune, epithelial, and stromal cell populations suggest that the clustering and annotation process effectively separated biologically meaningful cell identities.
- The consistency of marker expression with established literature further strengthens the reliability of these annotations for downstream analyses, particularly for exploring condition-specific changes in cell types (e.g., normal vs. tumor) or cell-cell interactions.
- Some markers, while specific to a broad category (e.g., pan-B cell or pan-T cell markers), also show differential expression patterns among their subsets, aiding in fine-grained distinctions. For example, specific transcription factors or co-receptors enable differentiation between T helper subsets.
4. Analysis of Copy Number Variations in Intestinal Epithelial and Unassigned Cells
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes estimated copy number variations (CNVs) in Intestinal Epithelial cells (identified as the tumor-origin cell type) and 'unassigned' cells, grouped by sample. The primary goal is to identify recurrent genomic amplifications or deletions across different samples, even within cell populations inferred to be largely diploid. The provided heatmap displays log2(Copy Number Ratio) values across genomic regions, and a summary highlights significantly amplified cytogenetic bands and their frequencies.
Visual Summary
The main visualization is a CNV heatmap showing log2(CNR) values across chromosomes (x-axis, ordered from 1 to 22) for various cell groups (y-axis). Each row represents a sample group, specifically focusing on "Intestinal Epithelial cell" and "unassigned" cell types, with a prefix indicating their inferred ploidy status (e.g., "Diploid T_cacX" or "Diploid B_cacX"). Red and yellow hues indicate copy number amplifications (log2(CNR) > 0), while blue hues indicate deletions (log2(CNR) < 0).
Key observations from the heatmap:
- Recurrent Amplifications: Several genomic regions show consistent amplification (red/yellow) across multiple samples. Notably, amplifications appear frequently on chromosomes 1, 8, 12, 19, and 20.
- Sample-Specific Patterns: While some regions show broad patterns, there are also variations in the intensity and extent of CNVs across different samples. For instance, Diploid T_cac1 exhibits distinct amplification patterns on chromosomes 8 and 19 compared to other Diploid T_cac samples.
- Ploidy Context: All displayed samples are prefixed with "Diploid", indicating that the majority of cells within these groups were inferred as diploid. However, the presence of distinct focal amplifications suggests that even in a predominantly diploid context, specific genomic regions can undergo copy number gains, which might be biologically significant.
- Chromosomal Locations: Specific cytogenetic bands, such as 1q21.3:1q22, 8q21.3:8q24.21, 12q24.22:12q24.31, 19q13.12:19q13.2, and 20p13:20p11.21, are highlighted with labels, indicating regions of interest.
The accompanying summary plot (right panel) provides a detailed view of significantly amplified regions:
- Frequency of Amplification (Bar Plot): This plot shows the frequency (proportion) of samples exhibiting amplification for specific cytogenetic bands. Regions on chromosomes 19q (19q13.12:19q13.2, 19q13.2:19q13.31, 19q13.32:19q13.41) show the highest frequency of amplification (1.00 for 19q13.12:19q13.2), meaning all three analyzed samples (T_cac1, T_cac3, T_cac8) displayed amplification in this region. Other frequently amplified regions include 1q21.3:1q22, 5q31.1:5q31.2, 8q21.3:8q24.21, 8q24.3:9p24.1, 12q24.22:12q24.31, 12q24.33:13q12.3, and 20p13:20p11.21, all with a frequency of 0.67 (present in 2 out of 3 samples).
- Copy Number Values per Sample (Heatmap): The smaller heatmap on the left shows the average log2(CNR) values for these specific cytogenetic bands across samples T_cac1, T_cac3, and T_cac8. It confirms amplification in these regions, with varying magnitudes (e.g., 19q13.12:19q13.2 showing high values across all three samples).
Biological Interpretation
The analysis specifically focuses on Intestinal Epithelial cells (the tumor-origin cell type in this dataset) and 'unassigned' cells. The observation of focal CNVs within these groups, even when largely inferred as "Diploid", is highly relevant to cancer biology. Many early-stage or less aggressive tumors can maintain an overall diploid karyotype while acquiring specific oncogenic CNVs.
- Recurrent Amplifications in Tumor Samples: The frequent amplifications observed on chromosomes 1, 8, 12, 19, and 20, particularly in the T_cac (tumor) samples, suggest these regions harbor genes that provide a selective advantage to tumor cells.
- Chromosome 8 Amplifications (8q21.3:8q24.21 and 8q24.3:9p24.1): These regions are highly significant as they encompass the *MYC* oncogene locus (8q24.21). *MYC* is a potent proto-oncogene frequently amplified and overexpressed in colorectal cancer, driving cell proliferation, growth, and survival. The mention of *INTS8* and *EIF3E* within the 8q21.3:8q24.21 region further points to potential drivers.
- *MYC* gene: GeneCards entry for MYC
- Chromosome 19 Amplifications (19q13.12:19q13.2, 19q13.2:19q13.31, 19q13.32:19q13.41): The high frequency (1.00) of amplification in 19q13.12:19q13.2 across the summarized samples indicates a highly recurrent event. Chromosome 19q amplifications have been implicated in various cancers, often affecting genes involved in cell cycle regulation and signaling pathways.
- Chromosome 1q21.3:1q22 Amplification: This region is a common site of amplification across many cancer types, often associated with aggressive tumor phenotypes. It can harbor genes like *S100A* family members which are involved in inflammation and cancer progression.
- Chromosome 20p13:20p11.21 Amplification: Amplifications on chromosome 20 are also frequently observed in colorectal cancer and may contain genes like *AURKA*, which plays a role in mitosis and is a target for cancer therapy.
- Implications for Tumor Development: The consistent detection of these focal amplifications in tumor-origin cells, even within what are broadly classified as diploid samples, suggests specific genomic alterations that contribute to tumor initiation or progression in the colon. These regions likely contain oncogenes whose increased copy number drives malignant transformation or enhances tumor cell fitness.
- "Unassigned" Cells: The inclusion of "unassigned" cells in the analysis is important. If these cells show similar CNV patterns to the Intestinal Epithelial cells, it could suggest that some 'unassigned' cells might also be tumor cells or tumor-adjacent epithelial cells with oncogenic potential. However, without further annotation, this remains an area for further investigation.
Clinical or Translational Implications
The identification of recurrent genomic amplifications, especially those involving known oncogenes like *MYC* on chromosome 8, offers valuable insights into the genetic landscape of colorectal cancer. These findings could potentially inform:
- Biomarker Discovery: The consistently amplified regions could serve as potential diagnostic or prognostic biomarkers for colorectal cancer, particularly in early stages or in tumors classified as diploid.
- Therapeutic Targeting: Genes residing within these amplified regions (e.g., *MYC* and others on 19q) might represent actionable therapeutic targets, even in tumors without overt aneuploidy. Further investigation into specific genes within these bands could pinpoint novel targets for precision oncology.
- Understanding Tumor Heterogeneity: Even within 'diploid' tumor cell populations, these focal CNVs highlight genomic heterogeneity that might contribute to differential responses to treatment or disease progression.
Annotation Notes
The use of ploidy_dec to label cell groups as "Diploid" provides an important context for interpreting the CNV heatmap. The presence of focal CNVs within these "Diploid" groups suggests that ploidy inference at a genome-wide level might not capture all biologically significant copy number changes. This highlights the importance of analyzing both gross aneuploidy and subtle, focal CNVs. The inclusion of "unassigned" cells means their CNV profile should be considered, as it might shed light on their true cellular identity and role in the tumor microenvironment.
5. CNV-Based UMAP Embedding and Cell Annotation Analysis in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a Uniform Manifold Approximation and Projection (UMAP) visualization of single-cell RNA-seq data, specifically embedding cells based on their Copy Number Variation (CNV) estimates (derived from obsm['X_cnv']). This CNV-based embedding allows us to explore the cellular landscape through the lens of genomic alterations, providing insights into cellular identity, ploidy status, and condition-specific patterns. The UMAP plots are colored by various cellular and sample annotations: major cell type, minor cell type, ploidy status, experimental condition (normal/tumor), and individual sample. The goal is to understand how these annotations align with the underlying CNV patterns.
Visual Summary
The UMAP plots, generated using CNV estimates, reveal distinct clustering patterns:
celltype_major & celltype_minor:
- A large, somewhat diffuse cluster occupies the left-to-middle region of the UMAP, predominantly composed of immune cells (T cell, B cell, Myeloid, Mast cell, ILC, NK, Plasma, DC) and stromal cells (Stromal cell, Fibroblast, Smooth muscle cell, Endothelial cell). These cell types generally appear intermingled within this large cluster, suggesting similar CNV profiles (likely diploid, see below).
- A distinct, tighter cluster is observed on the lower-right side of the UMAP. This cluster is overwhelmingly enriched for "Intestinal Epithelial cell" (major and minor cell type annotations). This separation strongly suggests that the epithelial cells possess CNV profiles distinct from the other cell types.
- "unassigned" cells are dispersed, but a notable portion overlaps with the main immune/stromal cluster.
ploidy_dec:
- The UMAP colored by ploidy_dec clearly shows that the tight cluster on the lower-right, dominated by Intestinal Epithelial cells, is almost exclusively labeled as Aneuploid (red).
- Conversely, the large, diffuse cluster on the left, containing immune and stromal cells, is predominantly labeled as Diploid (yellow).
- A small number of 'Unclear' cells (purple) are scattered. This strong segregation of aneuploid cells to a specific region of the CNV UMAP is a critical observation.
condition:
- When colored by condition, the distribution of 'normal' (red) and 'tumor' (purple) cells is evident.
- The aneuploid cluster on the lower-right, identified with Intestinal Epithelial cells, is almost entirely composed of cells from the tumor condition.
- The large, diploid cluster on the left shows a mix of both normal and tumor cells, with normal cells potentially slightly more enriched towards the far left. This indicates that tumor samples contain both diploid non-malignant cells (immune, stromal) and aneuploid malignant cells, while normal samples primarily consist of diploid cells.
sample:
- The sample plot reveals that cells from different samples are generally well-mixed within the large diploid cluster, suggesting common CNV patterns among normal host cells across samples.
- However, within the aneuploid (tumor epithelial) cluster on the lower-right, there is some degree of sample-specific grouping, indicating inter-sample heterogeneity in the specific CNV profiles of the tumor cells. For instance, cells from B_cac4, B_cac6, B_cac10, B_cac11, B_cac14, B_cac15 appear to contribute to the aneuploid cluster, representing different tumor samples.
Biological Interpretation
- Identification of Malignant Cells by CNV: The CNV-based UMAP effectively separates cells based on their ploidy status. The distinct cluster of aneuploid cells, predominantly Intestinal Epithelial cells from tumor samples, strongly suggests the successful identification of malignant tumor cells. Aneuploidy, a state of having an abnormal number of chromosomes, is a well-established hallmark of cancer, particularly in solid tumors like those originating from epithelial cells GeneCards: Aneuploidy.
- Cell Type Specificity of CNVs: The "Intestinal Epithelial cell" population, identified as the "Tumor origin celltype" in the data context, forms a distinct cluster characterized by aneuploidy and origin from tumor samples. This is consistent with their expected role as the cell type undergoing malignant transformation in colon cancer. Other cell types (immune cells, stromal cells, endothelial cells) primarily exhibit diploid profiles and cluster separately, as expected for non-malignant cells within the tumor microenvironment or normal tissue.
- Tumor Microenvironment Composition: The coexistence of diploid cells (immune, stromal, endothelial) from tumor samples within the larger diploid cluster, alongside aneuploid tumor cells, reflects the complex cellular composition of the tumor microenvironment. These diploid cells represent the host response and supporting stroma within the tumor.
- Inter-sample Heterogeneity in Tumor CNVs: While all identified tumor cells share the overarching feature of aneuploidy, the sample-specific grouping within the aneuploid cluster hints at diversity in the specific CNV landscapes between individual patient tumors. This genomic heterogeneity can influence tumor behavior, treatment response, and prognosis PubMed Search: Tumor heterogeneity CNV cancer.
Annotation Notes
- Robustness of Ploidy Annotation: The ploidy_dec annotation (Aneuploid/Diploid) appears highly consistent with the CNV-based UMAP embedding, validating the quality of this specific annotation. The clear separation of aneuploid cells strongly supports its accuracy.
- Cell Identity Confirmation: The alignment of "Intestinal Epithelial cell" with aneuploidy and tumor origin in the CNV embedding provides strong evidence for their malignant identity. This corroborates the tumor_origin_ind metadata.
- Embedding Utility: The CNV-based UMAP is highly effective in delineating distinct biological states (malignant vs. non-malignant cells) that are difficult to discern solely based on gene expression alone without explicit CNV estimation.
- Potential for Further Analysis: This robust identification of malignant cells based on CNVs sets a strong foundation for subsequent differential expression, pathway analysis, or cell-cell interaction studies, allowing researchers to specifically compare true tumor cells against their non-malignant counterparts or against normal epithelial cells.
6. Colon Tissue Minor Cell Type Population Analysis
[Analysis Visualization Results]...
Analysis Overview
이 분석은 단일 세포 RNA 시퀀싱 데이터를 사용하여 정상(normal) 및 종양(tumor) 대장 조직 샘플의 마이너 세포 유형 구성을 비교하는 막대 그래프를 제공합니다. 각 막대는 특정 샘플 내의 총 세포 수에 대한 각 세포 유형의 상대적 비율을 나타내어, 샘플 간 및 조건 간의 세포 구성 변화를 시각화합니다.
Visual Summary
주어진 막대 그래프는 정상 및 종양 조건에서 대장 조직의 마이너 세포 유형 구성에 대한 통찰력을 제공합니다.
정상 조직(normal)
- 대부분의 정상 샘플은 Intestinal Epithelial cell (담황색)이 가장 큰 비율을 차지하며, T cell CD4+ (밝은 청록색) 및 T cell CD8+ (짙은 청록색)과 같은 T 세포가 상당한 부분을 차지하고 있습니다.
- B cell (짙은 적색)은 일부 정상 샘플(예: B_cac10, B_cac11, B_cac14)에서 주목할 만한 존재감을 보이며, Plasma cell (밝은 녹색) 또한 다양한 비율로 나타납니다.
- Fibroblast (주황색), Macrophage (노란색), Endothelial cell (주황-적색), Dendritic cell (적색) 등 다른 세포 유형은 일반적으로 낮은 비율로 존재합니다.
종양 조직(tumor)
- Intestinal Epithelial cell의 비율은 대부분의 종양 샘플에서 정상 샘플에 비해 크게 감소했습니다. 이는 암세포의 증식과 정상 조직의 대체 가능성을 시사합니다. 하지만 일부 종양 샘플(예: T_cac1, T_cac7, T_cac8)에서는 여전히 상당한 비율을 유지하고 있습니다.
- Fibroblast는 여러 종양 샘플(예: T_cac2, T_cac3, T_cac1, T_cac7, T_cac8)에서 정상 샘플보다 더 높은 비율로 나타나, 종양 미세 환경(TME)에서 기질 세포의 증가를 시사합니다.
- T cell (CD4+ 및 CD8+)은 종양 샘플에서도 여전히 상당한 비율을 차지하며, CD4+ T 세포가 여러 샘플에서 두드러집니다. T 세포의 상대적 비율은 종양 샘플 간에 상당한 가변성을 보입니다.
- B cell 및 Plasma cell의 침윤은 종양 샘플에서 매우 가변적입니다. 일부 샘플에서는 거의 부재하지만, 다른 샘플(예: T_cac10, T_cac11, T_cac12, T_cac5, T_cac13, T_cac6, T_cac9, T_cac16, T_cac15, T_cac4)에서는 B 세포와 플라스마 세포가 눈에 띄게 증가했습니다.
- Macrophage (노란색) 및 Dendritic cell (적색)과 같은 골수성 세포도 종양 샘플에 존재하며, 이는 종양 관련 염증 및 면역 반응을 나타냅니다.
- Endothelial cell (주황-적색)의 존재는 종양 신생 혈관 형성(angiogenesis)과 일치합니다.
- 두 조건 모두에서 샘플 간의 상당한 이질성이 관찰되며, 이는 개별 환자의 생물학적 차이를 반영합니다.
Biological Interpretation
대장 조직에서 정상과 종양 조건 간의 마이너 세포 유형 구성 변화는 종양 미세 환경(TME)의 재편성을 강력하게 시사합니다.
- 상피세포 감소 및 종양 유래 세포의 변화: Intestinal Epithelial cell이 종양 기원 세포 유형으로 명시된 점을 감안할 때, 종양 샘플에서 이 세포 유형의 상대적 감소는 정상 상피 조직이 종양 세포에 의해 대체되거나, 샘플링 과정에서 종양 세포가 비악성 상피세포로 분류되지 않았을 가능성을 나타낼 수 있습니다. 종양 세포는 형태학적 및 유전자 발현 변화를 겪을 수 있어 기존 상피세포 마커 발현이 감소할 수 있습니다.
- 섬유아세포(Fibroblast)의 증가: 종양 샘플에서 섬유아세포의 증가 경향은 종양 미세 환경에서 암 관련 섬유아세포(CAFs)의 축적을 나타낼 수 있습니다. CAFs는 세포외 기질(ECM) 리모델링, 면역 억제, 종양 세포 증식 및 전이를 촉진함으로써 종양 진행에 중요한 역할을 합니다 PubMed search: Cancer-Associated Fibroblasts Colon Cancer.
- 면역 세포 침윤의 변화:
- T 세포: CD4+ 및 CD8+ T 세포는 정상 및 종양 조직 모두에서 중요한 구성 요소로 유지됩니다. 이는 종양 내 면역 반응의 지속적인 존재를 나타내지만, 이들 T 세포의 활성화 상태나 기능(예: 피로 T 세포, 조절 T 세포)은 추가적인 세부 분석(예: celltype_subset 또는 DEG 분석)이 필요합니다. CD8+ T 세포는 항종양 면역에 중요하며, 그 존재는 종종 긍정적인 예후와 관련이 있습니다.
- B 세포 및 플라스마 세포: 일부 종양 샘플에서 B 세포와 플라스마 세포의 눈에 띄는 증가는 종양 내 삼차 림프 구조(TLS)의 형성을 시사할 수 있습니다. TLS는 종양 미세 환경에서 항종양 면역 반응을 촉진하거나 조절할 수 있는 국소 면역 반응의 중요한 부위입니다 PubMed search: Tertiary Lymphoid Structures Tumor Immunity.
- 골수성 세포: Macrophage 및 Dendritic cell의 존재는 종양 관련 대식세포(TAMs) 및 수지상 세포의 역할을 강조합니다. TAMs는 종양 성장을 촉진하고 면역 억제를 유도할 수 있으며 PubMed search: Tumor-Associated Macrophages Colon Cancer, 수지상 세포는 면역 반응을 개시하거나 조절할 수 있습니다.
Clinical or Translational Implications
이러한 세포 유형 구성의 변화는 대장암의 진단, 예후 및 치료에 중요한 임상적 의미를 가집니다.
- 생체 지표 발굴: TME 내 특정 세포 유형의 상대적 비율은 잠재적인 예후 또는 예측 생체 지표로 사용될 수 있습니다. 예를 들어, 특정 유형의 면역 세포 침윤 패턴(예: CD8+ T 세포 대 조절 T 세포 비율, B 세포/플라스마 세포 존재 여부)은 환자의 생존율 또는 면역 치료 반응과 연관될 수 있습니다.
- 치료 전략 개발:
- 기질 표적 치료: 섬유아세포(CAFs)가 풍부한 종양은 기질 리모델링을 표적으로 하는 약물이나 CAFs의 기능을 억제하는 치료법에 반응할 수 있습니다.
- 면역 치료: T 세포, B 세포, 플라스마 세포 및 골수성 세포의 다양한 존재는 면역 체크포인트 억제제(ICI)와 같은 면역 치료에 대한 환자의 반응성을 예측하거나, 새로운 면역 요법 개발을 위한 통찰력을 제공할 수 있습니다. 특히 B 세포 및 플라스마 세포가 풍부한 종양은 TLS 형성 및 이에 따른 면역 반응 강화와 관련될 수 있으므로, ICI에 대한 반응 가능성이 더 높을 수 있습니다.
- 환자 층화: 세포 구성의 샘플 간 이질성은 대장암의 다양한 아형(subtype)이 존재하며, 개인 맞춤형 치료 접근법이 필요함을 시사합니다. 각 환자의 TME 프로파일을 특성화하는 것은 최적의 치료법을 선택하는 데 도움이 될 수 있습니다.
이러한 인구 분석은 TME의 기본 구성에 대한 중요한 초기 통찰력을 제공하며, 특정 세포 유형의 기능적 상태 및 상호 작용에 대한 추가 분석(예: DEG, GSEA, CCI)을 통해 보다 심층적인 기계적 이해와 임상적 관련성을 도출할 수 있습니다.
7. T Cell Subset Population Analysis in Colon Normal vs. Tumor Conditions
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a stacked barplot visualizing the relative proportions of T cell subsets, including other innate lymphoid cells (ILCs) and NK cells, within the major "T cell" population across individual samples from normal and tumor colon tissues. The aim is to identify shifts in immune cell composition associated with the disease state.
Visual Summary
The visualization displays the proportional distribution of various lymphoid subsets (T cells, ILCs, NK cells) within each sample, grouped by 'normal' and 'tumor' conditions. Each bar represents a sample, and the colored segments indicate the percentage contribution of each cell type, normalized to 100%.
- Overall Composition: Both normal and tumor samples are largely dominated by T cell populations, specifically T cell (Cytotoxic) and T cell (Naive) cells, which constitute the bulk of the lymphoid compartment. T cell (Treg) cells, Th1, and Th17 cells are also consistently present, albeit in smaller proportions. ILCs (ILC1, ILC2, ILC3 (NCR+/-), ILCreg, LTI) and NK cells generally represent minor fractions in most samples.
- Normal Condition: In normal colon samples, the composition appears relatively consistent across different individuals. T cell (Cytotoxic) and T cell (Naive) cells are prominent, and T cell (Treg) cells maintain a smaller, stable presence.
Tumor Condition Differences:
- Increased T cell (Treg) Proportions: A notable observation in the tumor samples is a generalized and often increased proportion of T cell (Treg) cells (dark blue segment) compared to most normal samples. This expansion is evident across many tumor samples, suggesting an enrichment of these suppressive immune cells in the tumor microenvironment.
- Variability in Cytotoxic/Naive T cells: While still abundant, the relative proportions of T cell (Cytotoxic) and T cell (Naive) cells appear more variable among tumor samples compared to normal samples. Some tumor samples show a slight decrease in the proportion of cytotoxic T cells relative to other subsets.
- Minor ILC/NK cell Shifts: ILCs and NK cells remain minor components. However, some tumor samples (e.g., T_cac12) show a slightly more pronounced presence of ILC1 (dark red) or ILC3 (NCR-) (orange-red) cells than typically observed in normal tissue, although this is not a universal trend across all tumor samples.
- Inter-sample Heterogeneity: There is greater heterogeneity in the lymphoid subset composition among individual tumor samples compared to the more uniform profiles seen in normal samples.
Biological Interpretation
The observed shifts in lymphoid cell populations provide critical insights into the immune landscape of colon cancer.
- T cell (Treg) Expansion in Tumor Microenvironment (TME): The consistent and often increased presence of T cell (Treg) cells in tumor samples is a highly significant finding. Regulatory T cells are known immunosuppressive cells that play a crucial role in maintaining immune tolerance and preventing autoimmunity. In the context of cancer, an expansion of Tregs within the TME is a common mechanism by which tumors evade anti-tumor immunity by suppressing the activity of effector T cells (like cytotoxic T cells) and other immune cells PubMed Search: regulatory T cells tumor microenvironment colorectal cancer. This suggests an immune-suppressive environment in the colon tumors.
- Implications for Anti-tumor Immunity: While cytotoxic T cells, which are crucial for direct killing of cancer cells, remain a major component, their variable and sometimes relatively reduced proportions in tumor samples, coupled with increased Tregs, could indicate a dysfunctional or exhausted anti-tumor immune response. Naive T cells, which are unprimed, also show variability, reflecting the dynamic immune activation state in the TME.
- Role of Other T Helper Subsets: The presence of Th1 and Th17 cells suggests ongoing inflammatory processes. Th1 cells are typically associated with anti-tumor immunity through IFN-$\gamma$ production, while Th17 cells can have dual pro- or anti-tumor roles depending on the cytokine milieu.
- Innate Lymphoid Cells (ILCs) and NK Cells: While less prominent, the subtle shifts in ILCs (e.g., ILC1, ILC3) in some tumor samples are noteworthy. ILC1s are IFN-$\gamma$ producing cells akin to Th1 cells and contribute to anti-tumor immunity. ILC3s are involved in mucosal immunity and can contribute to both protective and pathological inflammation GeneCards: ILC3. NK cells are innate cytotoxic cells that provide immediate defense against transformed cells GeneCards: NK cell. Their contribution suggests varying innate immune responses across tumors.
Clinical or Translational Implications
The findings have several important clinical and translational implications for colon cancer:
- Targeting Immunosuppression: The pronounced increase in T cell (Treg) cells in the tumor microenvironment highlights these cells as potential therapeutic targets. Strategies aimed at depleting or inhibiting Treg function could enhance anti-tumor immunity and improve responses to other immunotherapies PubMed Search: Treg depletion cancer therapy.
- Predictive Biomarker Potential: The relative proportion of T cell (Treg) cells, possibly in conjunction with cytotoxic T cells, could serve as a biomarker to predict patient prognosis or response to immunotherapy. Tumors with a higher Treg/cytotoxic T cell ratio might be less responsive to immune checkpoint blockade.
- Heterogeneity in Immune Response: The observed heterogeneity among tumor samples underscores the need for personalized approaches in cancer immunotherapy. Understanding the specific immune cell composition of an individual patient's tumor could guide treatment selection and combination strategies.
- Monitoring Treatment Efficacy: Changes in the proportions of T cell subsets, particularly Tregs and cytotoxic T cells, could be used to monitor the efficacy of immunotherapeutic interventions. A reduction in Tregs and/or an increase in cytotoxic T cells in the TME post-treatment would suggest a favorable immune response.
8. Macrophage Subset Population Analysis in Colon Normal vs. Tumor Tissues
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the proportional distribution of macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual normal and tumor samples from colon tissue. The single-cell RNA-seq data was analyzed to identify and quantify these macrophage populations, providing insights into potential shifts in the tumor microenvironment (TME).
Visual Summary
The stacked bar plot effectively displays the relative abundance of five distinct macrophage subsets—M1, M2A, M2B, M2C, and M2D—within each analyzed sample. Samples are grouped by condition (normal vs. tumor).
- Normal Samples: The macrophage populations in normal colon tissue samples exhibit variability, with M1 and M2A subtypes often being the most dominant. For instance, sample B_cac15 shows a very high proportion of M2A macrophages, while others like B_cac10 and B_cac11 have a substantial M1 presence. M2B, M2C, and M2D subsets are generally present in smaller, more variable proportions.
- Tumor Samples: In contrast, the tumor samples show a consistent and often dominant presence of Macrophage (M1) cells across nearly all tested tumor samples. M1 macrophages frequently constitute the largest fraction of the total macrophage population, often exceeding 40-50% and, in some cases, reaching up to 70% (e.g., T_cac12). While M2A proportions are generally lower than M1, other M2 subtypes (M2B, M2C, M2D) are also observed in varying, but notable, proportions across tumor samples, suggesting a mixed macrophage landscape. The M2D subset, in particular, appears more consistently present in tumor samples compared to normal.
Biological Interpretation
Macrophages are critical immune cells exhibiting significant plasticity, polarizing into various functional states (M1-like and M2-like) that profoundly influence cancer progression and immune responses in the tumor microenvironment.
- Shift Towards M1 Dominance in Colon Tumors: The most striking observation is the increased and often dominant proportion of M1 macrophages in the colon tumor samples compared to normal tissues. M1 macrophages are classically activated, pro-inflammatory, and generally associated with anti-tumor functions, including cytokine production (e.g., TNF-$\alpha$, IL-12) and direct tumoricidal activity [1]. This finding suggests that despite being in a tumor context, the macrophage landscape in these colon tumors is heavily skewed towards an M1-like phenotype, potentially indicating an active inflammatory response or an attempt by the host immune system to combat the tumor.
- Complex Macrophage Polarization: While M1 macrophages are prominent, the continued presence of M2-like subsets (M2A, M2B, M2C, M2D) in tumor samples indicates a complex and heterogeneous macrophage polarization state. M2 macrophages are broadly associated with immune suppression, angiogenesis, tissue repair, and promotion of tumor growth [2].
- M2A (alternative activation) is typically involved in allergic responses and tissue repair.
- M2B (immune-complex mediated) plays roles in immune regulation.
- M2C (deactivated/regulatory) is linked to immunosuppression and tissue remodeling.
- M2D (IL-6/VEGF-producing) is specifically associated with angiogenesis and promotion of tumor metastasis [3].
The co-existence of M1 and various M2 subsets highlights the dynamic and context-dependent nature of macrophage functions within the colon tumor microenvironment. This could imply a scenario where pro-inflammatory M1 responses are present, but their efficacy might be modulated or counteracted by the concurrent presence of immunosuppressive M2 populations.
Clinical or Translational Implications
The observed shifts in macrophage populations have significant implications for understanding colon cancer biology and developing targeted therapies.
- Prognostic and Predictive Biomarkers: A high proportion of M1 macrophages in colon tumors could potentially be a favorable prognostic indicator, given their anti-tumor functions. Conversely, the presence of specific M2 subsets, even if not dominant, might correlate with immune evasion or resistance to certain therapies. Further studies could explore the M1:M2 ratio as a biomarker for disease progression or response to treatment [4].
- Immunotherapeutic Strategies: The prevalence of M1 macrophages suggests an underlying inflammatory state that could potentially be harnessed or enhanced for anti-tumor therapy. Strategies aimed at sustaining or boosting M1 polarization, or re-educating M2 macrophages towards an M1 phenotype, could be explored. Conversely, even with high M1, targeting specific M2 subsets (e.g., M2D for angiogenesis) might still be beneficial in overcoming immunosuppression and improving therapeutic outcomes [5].
- Disease Specificity: The observed M1 dominance in colon tumors might represent a specific characteristic of colorectal cancer compared to other tumor types where M2 dominance is more commonly reported. Understanding this tissue- and disease-specific macrophage polarization is crucial for developing context-appropriate immunotherapies.
---
References:
- M1 Macrophages in Cancer:
PubMed search: M1 macrophages anti-tumor immunity cancer
- M2 Macrophages in Cancer:
PubMed search: M2 macrophages pro-tumor immunity cancer
- M2D Macrophages:
PubMed search: M2D macrophages tumor angiogenesis
- Macrophage Polarization as Biomarker:
PubMed search: macrophage M1 M2 ratio cancer prognosis
- Targeting Macrophages in Cancer Therapy:
PubMed search: macrophage targeting cancer therapy
9. T Cell Subset Population Shifts in Colon Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportional changes of various T cell subsets within colon tissue when comparing normal conditions to tumor conditions. The aim is to identify specific T cell populations that are significantly altered in the tumor microenvironment, which can provide insights into immune responses and potential immune evasion mechanisms in colon cancer. The results are presented as boxplots, showing the distribution of cell type proportions for each T cell subset across normal and tumor samples, along with statistical significance markers (p-values).
Visual Summary
The boxplots illustrate the relative proportions of T cell subsets (Tfh, Th22, Treg, Th17) in normal versus tumor colon samples.
- Tfh cells: Show a trend of slightly decreased proportion in tumor samples compared to normal samples (median proportion around 12% in tumor vs. 15% in normal), but this difference is not statistically significant (p = 0.10).
- Th22 cells: Exhibit a statistically significant increase in proportion within tumor samples (median around 5.5-6%) compared to normal samples (median around 3.5-4%) (p ≤ 0.01).
- Treg cells: Demonstrate a highly statistically significant enrichment in tumor samples (median around 8-9%) compared to normal samples (median around 2.5-3%) (p ≤ 0.001).
- Th17 cells: Also show a statistically significant increase in proportion in tumor samples (median around 9%) compared to normal samples (median around 4.5%) (p ≤ 0.01).
Notably, Th22, Treg, and Th17 cell populations all exhibit a significant increase in their relative proportions in the tumor microenvironment of the colon.
Biological Interpretation
The observed shifts in T cell subset proportions in colon tumor tissue suggest a significant re-programming of the local immune environment, often indicative of an adaptive immune response tailored by the tumor.
- Expansion of Immunosuppressive Treg cells: The most prominent finding is the highly significant increase in Regulatory T cells (Treg cells) within the tumor. Tregs are crucial for maintaining immune tolerance and suppressing effector T cell responses. Their enrichment in the tumor microenvironment (TME) is a well-established mechanism by which tumors evade anti-tumor immunity, often leading to a dampened immune attack against cancer cells. This is a common feature in many cancers, including colorectal cancer. PubMed Search: Treg cells colorectal cancer immune evasion
- Increase in Th17 cells: Th17 cells, characterized by their production of IL-17, exhibit a significant increase in the tumor. The role of Th17 cells in cancer is often context-dependent, sometimes promoting anti-tumor immunity but frequently associated with pro-tumorigenic inflammation, angiogenesis, and tumor cell survival, particularly in colorectal cancer. The elevated presence of Th17 cells in the colon TME could contribute to chronic inflammation that supports tumor growth. PubMed Search: Th17 cells colorectal cancer IL-17
- Elevation of Th22 cells: The significant increase in Th22 cells in tumor samples is also notable. Th22 cells produce IL-22, which plays a role in tissue repair, inflammation, and host defense. In the context of cancer, IL-22 can promote proliferation, survival, and migration of cancer cells, as well as influence the differentiation of immune cells, potentially contributing to tumor progression in colorectal cancer. PubMed Search: Th22 cells colorectal cancer IL-22
- Tfh cells: While Tfh cells show a non-significant trend of decrease, their primary role is in supporting B cell responses within lymphoid follicles. Their presence in the direct tumor infiltrate may be less critical for the immediate anti-tumor response compared to other T cell subsets.
Overall, the data points towards an immune landscape in colon tumors that is significantly skewed towards immunosuppression (high Treg) and pro-tumorigenic inflammation (high Th17 and Th22), collectively hindering effective anti-tumor immunity.
Clinical or Translational Implications
The findings have several potential clinical and translational implications for colon cancer:
- Prognostic Biomarkers: The increased proportions of Treg, Th17, and Th22 cells could serve as prognostic biomarkers, where higher frequencies might correlate with poorer patient outcomes due to their immunosuppressive or pro-tumorigenic functions.
- Therapeutic Targets: Targeting these T cell subsets or their associated cytokines could represent novel therapeutic strategies. For instance, depleting or inhibiting Treg function could enhance anti-tumor immunity, while modulating Th17 and Th22 responses might reduce pro-tumorigenic inflammation. Strategies to block IL-17 or IL-22, or to inhibit the signaling pathways critical for the survival and function of these T cell subsets, could be explored.
- Immunotherapy Response: Understanding the balance of these T cell subsets might help predict patient response to existing immunotherapies, such as immune checkpoint inhibitors. Tumors with a heavily skewed immunosuppressive TME might require combination therapies to overcome resistance.
10. Differential Macrophage Subset Proportions in Colon Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportional changes of specific macrophage subset populations, namely Mac (M2D), Mac (M2B), and Mac (M2A), between normal colon tissue and colon tumor conditions. Box plots are used to visualize the distribution of celltype proportions, with statistical significance indicated for observed differences. This provides insight into the shifts in the macrophage landscape within the tumor microenvironment.
Visual Summary
The box plots illustrate the celltype proportion for three distinct macrophage subsets when comparing normal and tumor conditions:
- Mac (M2D): The proportion of Mac (M2D) cells is significantly increased in the tumor samples compared to normal samples (p ≤ 0.05). In normal tissue, the median proportion is very low (around 2-3%), whereas in tumor tissue, it increases notably, with a median around 10-12%. There are also outliers with higher proportions in the tumor group.
- Mac (M2B): Similar to Mac (M2D), the proportion of Mac (M2B) cells also shows a statistically significant increase in tumor samples compared to normal samples (p ≤ 0.05). The median proportion in normal tissue is approximately 10%, which rises to about 18-20% in the tumor condition.
- Mac (M2A): In contrast to M2D and M2B, the proportion of Mac (M2A) cells is significantly decreased in tumor samples compared to normal samples (p ≤ 0.01). Normal colon tissue exhibits a higher median proportion of Mac (M2A) (around 45%), which drops substantially to a median of approximately 10-12% in the tumor samples.
Biological Interpretation
Macrophages are highly plastic immune cells that play diverse roles in tissue homeostasis, inflammation, and cancer. The observed shifts in macrophage subset proportions in the colon tumor microenvironment (TME) suggest a reprogramming of these cells, consistent with their known roles in tumor progression:
- Increase in Mac (M2D) and Mac (M2B) in Tumor: M2-polarized macrophages are broadly associated with immunosuppression, tumor growth, angiogenesis, and metastasis.
- Mac (M2D), often referred to as regulatory macrophages or tumor-associated macrophages (TAMs), are particularly known for their immunosuppressive properties, promoting T-cell anergy, fostering angiogenesis, and supporting tumor invasion and metastasis. Their significant increase in colon tumors aligns with the common finding of an elevated pro-tumorigenic macrophage presence in many cancers [1].
- Mac (M2B) macrophages possess a mixed phenotype, capable of producing both pro-inflammatory (e.g., TNF-α, IL-6) and anti-inflammatory (e.g., IL-10) cytokines. Their increase in the TME suggests a complex role, potentially contributing to chronic inflammation that can fuel tumor growth, while also participating in immune regulation that might favor immune evasion [2]. The production of IL-10, a key immunosuppressive cytokine, by M2B macrophages could contribute to the overall immunosuppressive environment.
- Decrease in Mac (M2A) in Tumor: M2A macrophages are primarily involved in allergic responses, parasitic infections, and wound healing, often characterized by their anti-inflammatory and tissue repair functions [3]. The significant reduction of Mac (M2A) in the tumor context suggests a loss of these protective or reparative macrophage phenotypes. This shift away from M2A could reflect the dysregulated nature of the TME, where normal tissue repair mechanisms are subverted, and the anti-tumor immune response is diminished. It might also indicate that the tumor environment actively suppresses the differentiation or maintenance of this macrophage subtype.
Collectively, these findings indicate a significant skewing of the macrophage population towards M2-like phenotypes (M2D and M2B) that generally support tumor growth and immune evasion, accompanied by a reduction in macrophages (M2A) typically associated with tissue repair and homeostatic functions. This pattern is a hallmark of many solid tumors, including colorectal cancer.
Clinical or Translational Implications
The observed shifts in macrophage subset proportions hold significant clinical and translational implications for colon cancer:
- Biomarkers for Disease Progression: The increased proportions of Mac (M2D) and Mac (M2B) macrophages could serve as potential prognostic biomarkers for colon cancer progression. A higher prevalence of these pro-tumorigenic subsets might correlate with more aggressive disease or poorer patient outcomes [1].
- Therapeutic Targets: The dominance of M2D and M2B macrophages suggests these subsets as attractive therapeutic targets. Strategies aimed at repolarizing M2 macrophages to an M1 (anti-tumor) phenotype, inhibiting their recruitment, or depleting them from the TME are actively being explored in cancer immunotherapy [4]. This might involve targeting specific signaling pathways or surface markers unique to these M2 subsets.
- Understanding Immune Evasion: The findings underscore a mechanism by which colon tumors evade immune surveillance – by fostering an environment rich in immunosuppressive macrophages. Therapeutic interventions that reverse this macrophage polarization could enhance the efficacy of other immunotherapies, such as checkpoint blockade [5].
References
- M2 Macrophages and Tumor Progression:
PubMed search: "M2 macrophages tumor progression" OR "TAMs cancer prognosis"
- M2B Macrophage Function:
PubMed search: "M2B macrophages cancer" OR "M2B macrophage IL-10"
- M2A Macrophage Function:
PubMed search: "M2A macrophages wound healing" OR "M2A macrophage tissue repair"
- Macrophage Repolarization in Cancer Therapy:
PubMed search: "macrophage repolarization cancer therapy" OR "TAM targeting immunotherapy"
- Macrophage Polarization and Immunotherapy:
PubMed search: "macrophage polarization checkpoint blockade" OR "TAMs immunotherapy resistance"
11. Ploidy Analysis of Tumor-Origin and Unassigned Cells in Normal and Tumor Colon Samples
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of Intestinal Epithelial cells (the designated tumor-origin cell type) and unassigned cells across various normal and tumor colon samples. The plot visualizes the proportional distribution of these ploidy states for the combined population of these selected cell types within each sample, grouped by condition.
Visual Summary
The bar plot displays the percentage of Aneuploid, Diploid, and Unclear cells within the specified cell populations (Intestinal Epithelial cells and unassigned cells) for each sample, stratified by 'normal' and 'tumor' conditions.
- Normal Samples: All analyzed normal samples (B_cac7, B_cac4, B_cac6, B_cac15, B_cac10, B_cac14, B_cac11) show nearly 100% Diploid populations within the selected cell types. There is virtually no detectable aneuploidy or unclear ploidy in these normal samples.
- Tumor Samples: In contrast, tumor samples exhibit notable heterogeneity in ploidy:
- A significant proportion of aneuploidy (represented by burgundy bars) is observed in several tumor samples, particularly T_cac3 (~58%), T_cac6 (~52%), T_cac1 (~44%), T_cac8 (~22%), and T_cac16 (~20%).
- Other tumor samples (T_cac4, T_cac9, T_cac2, T_cac14, T_cac15, T_cac11, T_cac12, T_cac13, T_cac10, T_cac5, T_cac7) are predominantly Diploid, similar to normal samples, with minimal to no aneuploidy.
- A very small "Unclear" population (light green) is visible in a few tumor samples (e.g., T_cac3, T_cac6), but it constitutes a minor fraction.
Biological Interpretation
The observed ploidy patterns align well with the expected genetic characteristics of normal and cancerous tissues, especially concerning the designated tumor-origin Intestinal Epithelial cells.
- Normal Tissue Stability: The near-exclusive presence of diploid cells in normal colon samples reflects the genetic stability of healthy tissues. Normal intestinal epithelial cells, which are constantly renewing, maintain a stable diploid genome to ensure proper function and prevent neoplastic transformation.
- Tumor-Associated Aneuploidy: The prevalence of aneuploidy in several tumor samples is a hallmark of cancer and indicates genomic instability. Aneuploidy, defined as an abnormal number of chromosomes, is a common feature in many solid tumors, including colorectal cancer, and is often associated with tumor progression, increased aggressiveness, and resistance to therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900984/. The detection of aneuploid cells within the 'Intestinal Epithelial cell' population strongly supports their malignant transformation and cancerous nature.
- Tumor Heterogeneity: The variability in aneuploidy levels among different tumor samples (some highly aneuploid, others largely diploid) highlights the intrinsic heterogeneity within cancer. This could be due to:
- Variations in Tumor Purity/Stage: Samples with high diploidy might have a lower proportion of actual tumor cells in the analyzed population (e.g., higher stromal or immune cell contamination that are also selected if unassigned cells are included and are non-epithelial) or represent less advanced tumors.
- Subtype Differences: Different molecular subtypes of colorectal cancer exhibit varying degrees of genomic instability, with some being more aneuploid than others.
- CNV Inference Limitations: The ploidy inference is based on CNV estimates (obsm['X_cnv']) and might have limitations in detecting aneuploidy in all tumor contexts, especially for focal CNVs or low-purity samples.
- Role of Unassigned Cells: While the focus is on Intestinal Epithelial cells as tumor-origin, the inclusion of "unassigned" cells means that any aneuploidy observed could also potentially originate from these unassigned populations if they too have undergone malignant transformation or are stromal cells responding to the tumor microenvironment with genomic alterations. However, given that aneuploidy is largely absent in normal samples, it strongly implicates the tumor context.
Clinical or Translational Implications
- Biomarker for Malignancy: The detection of aneuploidy in Intestinal Epithelial cells serves as a robust indicator of malignancy and can be a valuable diagnostic or prognostic biomarker in colorectal cancer.
- Treatment Stratification: Understanding the ploidy status and genomic instability of tumor cells could potentially guide treatment strategies. Tumors with high aneuploidy might respond differently to chemotherapy or targeted therapies compared to diploid tumors.
- Monitoring Disease Progression: Tracking the emergence or increase of aneuploidy in Intestinal Epithelial cells could provide insights into disease progression or recurrence.
- Research into Genomic Instability: This analysis highlights specific tumor samples with high levels of aneuploidy, making them interesting candidates for further investigation into the mechanisms driving genomic instability in colorectal cancer.
12. Normal Colon Cell-Cell Interaction Patterns Focused on Epithelial and T Cells
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates significant cell-cell interaction (CCI) patterns within the normal colon microenvironment, focusing on Intestinal Epithelial cells (specifically "Diploid Intestinal Epi" as the tumor-origin proxy in normal tissue) and key immune populations (CD4+ and CD8+ T cells). Fibroblasts and Macrophages were also requested but are not prominently displayed in the top 80 interactions for the normal condition plot. The dot plot visualizes the strength (mean expression) and significance (p-value) of ligand-receptor interactions between specified cell type pairs.
Visual Summary
The provided dot plot for the "normal" condition highlights a robust network of interactions primarily among T cells (CD8+, CD4+) and between T cells and Diploid Intestinal Epithelial cells. Homotypic interactions within T cell populations and within Diploid Intestinal Epithelial cells are also observed.
Prominent Interactions across Multiple Cell Pairs:
- Prostaglandin E2 (PGE2) Signaling: Interactions involving Prostaglandin E2 synthesized by PTGES2 or PTGES3 and recognized by PTGER2 or PTGER4 are highly prevalent, showing strong mean expression (indicated by bright green/yellow dots) and high significance (larger dot sizes) across homotypic T cell pairs, homotypic Intestinal Epithelial cell pairs, and heterotypic T cell-Intestinal Epithelial cell pairs.
- HLA-E mediated interactions: HLA-E interacting with CD94:NKG2A and CD94:NKG2E are frequently observed, particularly in T cell homotypic interactions and interactions between T cells and Diploid Intestinal Epithelial cells.
- Immune Checkpoint & Adhesion Molecules: VSIR (VISTA) interacting with HLA-E/HLA-F, CD58-CD2, CEACAM5-CD8A, and CDH1_integrin_aEb7_complex are also present, reflecting immune regulation and cell adhesion.
Key Cell-Cell Interaction Patterns:
- T cell Homotypic Interactions (e.g., T CD8+|T CD8+, T CD4+|T CD4+, T CD8+|T CD4+): Exhibit numerous significant interactions, suggesting active self-regulation and communication within T cell compartments. Prostaglandin E2 pathways, CD58-CD2, HLA-E interactions, and VSIR-HLA-E/F are particularly notable.
- Heterotypic T cell - Diploid Intestinal Epithelial cell Interactions: Show a substantial number of interactions, indicating active crosstalk between the immune system and the epithelial barrier. Common themes include Prostaglandin E2 signaling, HLA-E interactions (e.g., T CD8+|Diploid Intestinal Epi with HLA-E - CD94:NKG2A), and adhesion molecules (e.g., CEACAM5-CD8A).
- Diploid Intestinal Epithelial cell Homotypic Interactions: While fewer interactions are shown compared to T cells, important interactions like APLP2-PIGR, APP-SORL1, CEACAM5-CEACAM1, DSC2-DSG2, CDH1_integrin_aEb7_complex, and prostaglandin E2 pathways are present, indicative of epithelial integrity and self-regulation.
- Absence of Fibroblast and Macrophage Interactions: It's important to note that despite being included in the target_cells parameter, cell pairs involving Fibroblasts and Macrophages are not among the top 80 most significant and highly expressed interactions displayed for the normal condition in this specific plot. This may indicate their interactions with Intestinal Epithelial cells or T cells are less dominant or less significant in the normal colon, or were filtered out by the parameters (n_pairs_to_show, pval_cutoff, mean_cutoff).
Biological Interpretation
The observed CCI patterns in the normal colon tissue provide insights into the maintenance of tissue homeostasis and immune surveillance.
- Immune Homeostasis and Surveillance: The extensive homotypic T cell interactions (e.g., CD58-CD2) underscore the importance of direct T-T cell communication for maintaining T cell activation states and coordinating immune responses in the gut. The presence of HLA-E interactions with NKG2A/E on T cells and VSIR-HLA-E/F interactions suggests a crucial role for immune checkpoints in preventing over-activation and maintaining immune tolerance within the intestinal environment, which is constantly exposed to commensal microbiota and food antigens. PubMed search: HLA-E NKG2A immune tolerance gut
- Epithelial-Immune Crosstalk for Barrier Function: The reciprocal interactions between Diploid Intestinal Epithelial cells and T cells are vital for the integrity and defense of the intestinal barrier. Epithelial cells can present antigens or express regulatory molecules (e.g., HLA-E, CEACAMs) that modulate local immune responses. This constant communication helps the immune system to distinguish between harmless and harmful stimuli, crucial for gut health. Interactions like CEACAM5-CD8A could be involved in T cell recruitment or activation close to the epithelium. GeneCards: CEACAM5
- Widespread Role of Prostaglandin E2 Signaling: The strong and pervasive signal of PGE2 via its receptors (PTGER2/4) across almost all identified cell pairs highlights PGE2 as a key signaling molecule in the normal colon. PGE2 is a lipid mediator with diverse roles, including regulating inflammation, immune cell function (both pro- and anti-inflammatory effects depending on context and receptor expressed), and epithelial cell proliferation/differentiation. In a normal state, this broad signaling likely contributes to balancing immune responses, maintaining epithelial integrity, and facilitating tissue repair. PubMed search: Prostaglandin E2 gut homeostasis
- Epithelial Barrier Maintenance: Homotypic interactions among Diploid Intestinal Epithelial cells (e.g., CEACAM5-CEACAM1, DSC2-DSG2, CDH1_integrin_aEb7_complex) are critical for maintaining the tight junctions and cellular adhesion that form the physical barrier of the intestinal lining, preventing uncontrolled translocation of luminal contents.
Clinical or Translational Implications
Understanding the baseline CCI in normal colon tissue is fundamental for discerning pathological changes in disease states such as inflammatory bowel disease (IBD) or colorectal cancer (CRC).
- Therapeutic Target Identification: The prominent role of Prostaglandin E2 signaling suggests it could be a significant pathway to target for modulating immune responses or promoting epithelial health. In conditions where PGE2 signaling is dysregulated (e.g., excessive inflammation in IBD or tumor promotion in CRC), therapeutic interventions aimed at modulating PGE2 synthesis or receptor activity could be explored.
- Immune Checkpoint Modulation: The presence of immune checkpoints like VSIR-HLA-E/F and HLA-E-NKG2A/E interactions in normal tissue provides a baseline for evaluating their potential role in immune evasion by tumors or in the pathogenesis of autoimmune diseases. In cancer, aberrant activation of these inhibitory pathways could suppress anti-tumor immunity, making them potential targets for immunotherapy. GeneCards: VSIR
- Biomarker Discovery: Differences in the strength or presence of these interactions in disease conditions compared to normal tissue could serve as potential diagnostic or prognostic biomarkers. For instance, altered expression of specific adhesion molecules or PGE2 receptors in tumor-associated cells could indicate disease progression.
- Understanding Immune Tolerance: The findings emphasize the intricate balance of immune activation and suppression required for gut health. Therapeutic strategies for gut-related diseases need to consider how they might impact these fine-tuned interactions to avoid disrupting the delicate immune tolerance mechanisms.
13. Tumor 미세환경 내 Cell-Cell 상호작용 분석: 주요 Ligand-Receptor 쌍 및 생물학적 함의
[Analysis Visualization Results]...
Analysis Overview
본 분석은 단일 세포 RNA 시퀀싱 데이터를 기반으로 종양(tumor) 조건에서 세포 간 상호작용(Cell-Cell Interaction, CCI)을 시각화한 결과입니다. plot_cci_dots 툴을 사용하여 CellPhoneDB에서 예측된 리간드-수용체 쌍 상호작용 중 가장 유의미하고 발현량이 높은 상위 80개를 도트 플롯으로 나타냈습니다. 이 플롯은 각 상호작용의 통계적 유의성(-log10(p-value), 점 크기)과 발현량(log2(mean), 점 색상)을 동시에 보여주어 종양 미세환경 내 세포 간 커뮤니케이션 네트워크를 이해하는 데 중요한 통찰력을 제공합니다. 특히, expand_ploidy_from_tumor_origin 파라미터가 적용되어 종양 기원 세포인 장 상피 세포(Intestinal Epithelial cell)가 이배체(Diploid) 여부에 따라 구분되어 분석에 포함되었습니다.
Visual Summary
제공된 도트 플롯은 종양 조건에서 다양한 세포 유형(T CD8+, T CD4+, Plasma cell, B cell, Diploid Intestinal Epi) 간의 리간드-수용체 상호작용을 나타냅니다.
- 주요 상호작용 세포 유형: T 세포(CD4+ 및 CD8+), 형질세포(Plasma cell), B 세포, 그리고 이배체 장 상피 세포(Diploid Intestinal Epi)가 상호작용에 활발하게 참여하고 있음이 관찰됩니다. 이는 대장암 종양 미세환경에서 면역 세포와 상피 세포 간의 복잡한 통신을 시사합니다.
유의미하고 발현량이 높은 상호작용
- CCL5-CCR4: T CD8+ 세포 간, T CD4+ 세포 간의 동종(homotypic) 상호작용에서 매우 높은 유의성(큰 점)과 발현량(노란색)을 보입니다. CCL5는 T 세포 유인 및 활성화와 관련된 케모카인입니다.
- CCL20-CCR6: T CD4+ 세포와 이배체 장 상피 세포 간에 높은 유의성과 발현량을 나타냅니다. CCL20은 면역 세포 트래피킹에 관여합니다.
- CDH1_integrin_aEb7_complex: 이배체 장 상피 세포와 T CD8+ 및 T CD4+ 세포 간에 높은 유의성과 발현량을 보입니다. 이는 상피 세포와 T 세포 간의 접착에 중요한 역할을 합니다.
- HLA-E_NKG2A: T CD4+, T CD8+ 세포 간 및 T CD8+ 세포와 이배체 장 상피 세포 간의 상호작용에서 여러 군데에서 높은 유의성을 보이며, 면역 회피 메커니즘과 연관될 수 있습니다.
- CEACAM 계열: CEACAM5, CEACAM6 등 여러 CEACAM 분자들이 형질세포와 이배체 장 상피 세포, 또는 T 세포와 이배체 장 상피 세포 간의 상호작용에서 유의미하게 나타납니다. CEACAM은 세포 접착, 신호 전달 및 면역 조절에 관여합니다.
- ProstaglandinE2_byPTGES2_PTGER4: T CD4+ 세포와 이배체 장 상피 세포, T CD4+ 세포와 형질세포 간에 높은 유의성을 가집니다. Prostaglandin E2 (PGE2)는 종양 미세환경에서 면역 억제에 기여하는 강력한 면역 조절 물질입니다.
- APLP2_PIGR: 이배체 장 상피 세포와 T CD4+ 세포 간, 그리고 이배체 장 상피 세포 자체의 동종 상호작용에서 유의미하게 나타납니다. PIGR은 상피 세포에서 IgA 수송에 관여합니다.
- SIRPG_CD47: 형질세포와 T CD8+ 세포 간에 유의미한 상호작용으로 나타나며, "나를 먹지 마(don't eat me)" 신호와 연관됩니다.
Biological Interpretation
관찰된 세포-세포 상호작용은 대장암 종양 미세환경(TME)의 복잡한 면역 조절 및 세포 생물학적 과정을 반영합니다.
면역 회피 및 억제 메커니즘
- HLA-E–NKG2A 축: 종양 세포나 항원 제시 세포에서 발현되는 HLA-E는 NK 세포 및 일부 T 세포의 NKG2A 수용체와 결합하여 이들의 세포 독성 기능을 억제합니다. 이 상호작용의 높은 유의성은 대장암에서 종양 면역 회피의 중요한 경로임을 시사합니다. PubMed search: HLA-E NKG2A tumor immune evasion
- ProstaglandinE2 (PGE2)-PTGER4 신호: PGE2는 종양 세포 및 기질 세포에 의해 생성되며, T 세포와 같은 면역 세포의 PTGER4(EP4) 수용체를 통해 작용하여 면역 억제, 혈관 신생 및 종양 성장을 촉진할 수 있습니다. 이는 종양 미세환경이 면역 억제적인 특성을 가질 수 있음을 나타냅니다. GeneCards: PTGER4
- SIRPG–CD47 신호: CD47은 많은 암세포에서 높게 발현되어 면역 세포(대식세포 등)의 SIRPα(SIRPG)와 결합하여 포식 작용을 억제하는 "나를 먹지 마" 신호입니다. 이는 종양 세포가 면역 감시를 회피하는 전략으로 활용될 수 있음을 보여줍니다. GeneCards: CD47
세포 접착 및 이동
- CDH1-integrin αEβ7 복합체: 상피 세포의 E-cadherin(CDH1)은 T 세포의 integrin αEβ7과 결합하여 조직 상주 기억 T 세포(Trm)가 상피 조직, 특히 장에 머무는 데 필수적인 역할을 합니다. 이 상호작용은 T 세포의 종양 침윤 및 유지에 중요할 수 있습니다. PubMed search: E-cadherin integrin aEb7 T cells gut
- CEACAM 계열: CEACAM 단백질은 대장암을 포함한 여러 암에서 과발현되는 경우가 많으며, 세포 접착, 증식, 면역 조절에 관여합니다. 이들의 광범위한 상호작용은 종양 진행에 있어 다면적인 역할을 시사합니다. GeneCards: CEACAM5
케모카인 신호 전달
- CCL20-CCR6: 상피 세포에서 생성되는 CCL20은 T 세포, B 세포 등 CCR6+ 면역 세포를 유인합니다. 종양 맥락에서 이 축은 면역 세포 침윤에 기여하지만, 그 역할은 항종양성일 수도 있고, 면역 억제성일 수도 있습니다.
- CCL5-CCR4: CCL5는 T 세포를 포함한 다양한 면역 세포를 유인하는 강력한 케모카인입니다. T 세포 간 동종 상호작용에서의 높은 발현은 종양 미세환경 내 활발한 T 세포 모집 및 통신을 의미합니다. GeneCards: CCL5
Clinical or Translational Implications
이러한 세포-세포 상호작용 분석 결과는 대장암의 진단, 예후 예측 및 새로운 치료 전략 개발에 중요한 단서를 제공할 수 있습니다.
- 치료 표적 발굴: HLA-E–NKG2A, PGE2–PTGER4, SIRPG–CD47 및 CEACAM 계열과 같이 면역 회피 또는 종양 촉진에 관여하는 것으로 보이는 리간드-수용체 쌍은 새로운 면역 치료제 또는 병용 요법의 잠재적인 표적이 될 수 있습니다. 이러한 상호작용을 차단함으로써 항종양 면역 반응을 강화할 수 있습니다.
- 바이오마커 개발: 특정 세포 간 상호작용의 유의성 또는 발현 강도는 대장암 환자의 특정 치료에 대한 반응 예측 또는 예후 인자로 활용될 수 있습니다. 예를 들어, PGE2-PTGER4 신호의 활성화는 특정 면역 치료에 대한 저항성을 예측할 수 있습니다.
- 종양 면역 이해 증진: 이 분석은 종양 미세환경 내 다양한 면역 세포 및 상피 세포가 어떻게 상호작용하여 종양 진행을 조절하는지에 대한 심도 있는 이해를 제공합니다. 이는 다중 경로를 표적으로 하는 복합 치료 전략을 수립하는 데 기여할 수 있습니다.
- 실험적 검증 필요성: computationally 예측된 이러한 상호작용들은 공동 배양 시스템, 리포터 분석 또는 *in vivo* 모델과 같은 추가적인 실험적 검증을 통해 대장암에서의 기능적 관련성을 확인하는 것이 중요합니다.
14. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Related Genes in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) using CellPhoneDB for a focused set of immune checkpoint and cell cycle-related genes within normal and tumor colon tissues. The goal is to identify significant ligand-receptor interactions involving these specific pathways between different cell types present in the colon microenvironment and observe how these interactions differ between healthy and diseased states. The plot_cci_dots tool was used to visualize the most significant interactions based on p-value and mean expression, aggregating results by 'condition'.
Visual Summary
The dot plots display significant cell-cell interactions for the specified immune checkpoint and cell cycle-related genes. The size of the dot represents the negative log10 of the p-value (-log10(p)), indicating statistical significance (larger dots mean smaller p-values), while the color intensity represents the log2 of the mean expression (log2(m)) of the interacting ligand-receptor pair.
CCI for Normal Condition:
- Interactions: Two distinct interaction groups are observed: IFNG_Type_II_IFNR and LCK_CD8_receptor.
- Cell Pairs for IFNG_Type_II_IFNR: Primarily involves T CD8+ cells interacting with other T CD8+ cells, and T CD8+ cells interacting with B cells. The log2(m) values range from approximately 0.7 to 0.9.
- Cell Pairs for LCK_CD8_receptor: Involves T CD8+ cells interacting with other T CD8+ cells, T CD8+ cells interacting with B cells, and T CD4+ cells interacting with T CD8+ cells. The log2(m) values are slightly higher, ranging from approximately 0.9 to 1.0.
- Significance: All observed interactions in the normal condition show high statistical significance, indicated by the large, dark black dots (p-value < 1e-10).
CCI for Tumor Condition:
- Interactions: Only one interaction group, LCK_CD8_receptor, is observed. The IFNG_Type_II_IFNR interaction is absent in the tumor context under the displayed criteria.
- Cell Pairs for LCK_CD8_receptor: The interactions are restricted to T CD8+ | T CD8+ and T CD4+ | T CD8+ cell pairs. The interaction between T CD8+ | B cell seen in normal tissue is no longer present.
- Mean Expression: The log2(m) values for LCK_CD8_receptor interactions are consistently high at 1.0, suggesting potentially higher or more uniform expression levels of these interaction components in the tumor.
- Significance: Similar to normal, all LCK_CD8_receptor interactions in the tumor condition are highly statistically significant.
Comparison:
A key difference is the absence of IFNG_Type_II_IFNR interactions in the tumor condition, which were present in normal tissue. For LCK_CD8_receptor interactions, the mean expression appears higher in the tumor (uniformly 1.0) compared to normal (0.9-1.0), and the T CD8+ | B cell interaction is lost in the tumor microenvironment.
Biological Interpretation
The analysis, focused on immune checkpoint and cell cycle-related genes, reveals specific interactions that are active in normal colon tissue and undergo significant changes in the tumor microenvironment. Notably, despite a broad list of target genes, only a select few interactions met the display criteria, suggesting that many canonical immune checkpoint or cell cycle interactions might not be the most prominent ligand-receptor events in this specific dataset or context.
- IFN-γ Signaling (IFNG_Type_II_IFNR):
- In normal colon, the presence of IFNG_Type_II_IFNR interactions between T CD8+ cells (self-interaction and with B cells) indicates active interferon-gamma signaling. Interferon-gamma (IFN-γ) is a critical cytokine produced primarily by T cells and NK cells, essential for antiviral and anti-tumor immunity. It activates macrophages, upregulates MHC class I and II expression, and promotes immune cell maturation and function [GeneCards].
- The absence of IFNG_Type_II_IFNR interactions in the tumor microenvironment is a significant finding. This suggests a potential suppression or dysregulation of IFN-γ signaling, which is crucial for immune surveillance and anti-tumor responses. Loss of this signaling pathway could contribute to immune evasion by tumor cells.
- LCK and CD8-mediated Receptor Signaling (LCK_CD8_receptor):
- LCK (Lymphocyte-specific protein tyrosine kinase) is an intracellular non-receptor tyrosine kinase that plays a pivotal role in T cell activation and development, particularly in signaling pathways downstream of the T cell receptor (TCR) and CD4/CD8 co-receptors [GeneCards]. The term LCK_CD8_receptor likely refers to ligand-receptor complexes that involve the CD8 co-receptor and signal through LCK.
- In normal colon, these interactions occur between T CD8+ cells (self-interaction), T CD8+ and B cells, and T CD4+ and T CD8+ cells. This reflects normal T cell communication and potential cross-talk with B cells, important for coordinated immune responses.
- In the tumor microenvironment, LCK_CD8_receptor interactions are still highly significant and show increased mean expression (log2(m) = 1.0). However, the interaction involving B cells (T CD8+ | B cell) is lost, suggesting an alteration in the cellular landscape and communication patterns. The persistent T CD8+ self-interactions and T CD4+ | T CD8+ interactions indicate that CD8+ T cells remain present and engaged in intra-T cell communication, potentially reflecting ongoing T cell activation, proliferation, or exhaustion within the tumor. The increased mean expression could reflect higher abundance of these signaling components in the tumor-infiltrating T cells or increased engagement.
- Overall Context of Target Genes:
- The user query specifically targeted "immune checkpoint and cell cycle pathway-related genes." While IFN-γ and LCK are integral to immune responses, the visual output did not prominently feature direct ligand-receptor pairs of canonical immune checkpoints (e.g., PD-1/PD-L1, CTLA-4) or cell cycle regulators from the extensive list provided. This implies that within the defined significance and expression thresholds, these particular interactions were either not as statistically significant, not as abundantly expressed, or were outranked by the displayed interactions in terms of the n_pairs_to_show parameter. This is an important consideration when interpreting the completeness of the immune checkpoint and cell cycle landscape from these specific results.
Clinical or Translational Implications
- Impaired IFN-γ Signaling in Tumor: The striking absence of IFNG_Type_II_IFNR interactions in tumor tissue highlights a potential mechanism of immune evasion. Tumors often develop strategies to suppress IFN-γ production or signaling, leading to a "cold" tumor microenvironment less susceptible to immune attack.
- Therapeutic implications: Strategies aimed at restoring or enhancing IFN-γ signaling, such as direct administration of IFN-γ, use of IFN-γ-inducing agents, or gene therapies to boost its production by immune cells, could be beneficial. Such approaches might enhance the efficacy of other immunotherapies [PubMed search: Interferon gamma therapy cancer immunity].
- Altered T Cell Communication in Tumor: The sustained but reconfigured LCK_CD8_receptor interactions, with increased mean expression and loss of B cell partnership in the tumor, indicate ongoing T cell activity but also suggest a dysfunctional or rewired immune context. The CD8+ T cells are crucial for directly killing tumor cells.
- Therapeutic implications: Understanding the precise ligands and receptors involved in these LCK/CD8-mediated interactions could uncover novel targets to modulate T cell function in the tumor. For example, enhancing productive T CD4+ | T CD8+ collaboration or restoring beneficial T CD8+ | B cell interactions could improve anti-tumor immunity. Targeting LCK activity directly or indirectly could also be considered, given its central role in T cell activation, although systemic inhibition might have broad immunological side effects.
- Prioritization of Targets: The specific appearance of IFNG and LCK-related interactions, while canonical immune checkpoint molecules like PD-1/PD-L1 and CTLA-4 from the input list are not shown, suggests that in this particular colon cancer dataset, these upstream or core T cell activation pathways might be more dysregulated at the ligand-receptor level than the canonical checkpoints, or simply more statistically robust in this analysis setting. This re-prioritization could guide further investigation into IFNG biology or specific LCK-dependent pathways for therapeutic intervention in colon cancer.
15. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates statistically significant differences in cell-cell interactions (CCI) between normal and tumor conditions within colon tissue, focusing on major immune and stromal cell types. The dot plot visualizes the top 25 most significantly different CCI pairs for each condition, selected based on their minimum p-value. The size of each dot represents the statistical significance (negative log10 p-value), and the color intensity indicates the standardized mean interaction strength across samples. The interacting cell types include T cells (CD4+, CD8+), B cells, Plasma cells, ILCs, Fibroblasts, Macrophages, Endothelial cells, Mast cells, Smooth muscle cells, NK cells, Dendritic cells, and Intestinal Epithelial cells (specifically, diploid epithelial cells, as denoted by Ent.Epi (Dip)). The AnnData context indicates that Intestinal Epithelial cells are the tumor origin cell type, making their interactions particularly relevant.
Visual Summary
The dot plot displays a distinct pattern of cell-cell interactions, clearly separating interactions characteristic of the "normal" condition from those characteristic of the "tumor" condition.
- Distinct Condition-Specific Clusters: Two large blue boxes highlight the primary observation:
- The top-left box encompasses cell-cell interactions predominantly observed and statistically significant in "normal" samples. These interactions show larger, darker red dots within the "normal" sample rows and are largely absent or weak in "tumor" samples.
- The bottom-right box includes cell-cell interactions that are highly active and significant in "tumor" samples. These interactions appear as larger, darker red dots within the "tumor" sample rows and are less prominent in "normal" samples.
- Interaction Strength and Significance:
- Dot Color (Standardized Sample Mean): Darker red dots indicate a higher standardized mean interaction strength for a given ligand-receptor pair. This suggests more prevalent or stronger signaling.
- Dot Size (-log10(p)): Larger dots represent more statistically significant differences. The scale indicates p-values ranging from 10^-1 to 10^-300, highlighting highly significant findings.
- Key Interacting Cell Types: The x-axis labels reveal interactions primarily between various immune cells (T cells, B cells, Plasma cells) and stromal cells, as well as with Intestinal Epithelial cells (Diploid, Ent.Epi (Dip)). This underscores the complex interplay within the tissue microenvironment.
Biological Interpretation
Normal-Associated Cell-Cell Interactions
Interactions prominent in normal colon tissue largely involve immune surveillance, cell adhesion, and homeostatic regulation. These often reflect a healthy, organized immune microenvironment.
Immune Surveillance & Adhesion:
- HLA-E-CD94:NKG2C-T CD8+: This interaction involves HLA-E presented by target cells and the NKG2C receptor on CD8+ T cells. While NKG2C is typically on NK cells, certain CD8+ T cells can express it, indicating adaptive immune surveillance and potential recognition of stressed or infected cells. PubMed search: HLA-E NKG2C T cell
- ICAM1-SPN-T CD8+ and ICAM1_integrin_alb2_complex-T CD8+|T CD8+: ICAM1 (Intercellular Adhesion Molecule 1) interactions with SPN (Sialomucin) or integrin alpha L beta 2 complex (LFA-1) on T cells are crucial for leukocyte adhesion, T cell activation, and migration within tissues, supporting effective immune responses. GeneCards: ICAM1
B Cell Activation & Regulation:
- SEMA4D-CD72-Plasma|B cell and SEMA4D-CD72-B cell|B cell: Semaphorin 4D (SEMA4D) on T cells or other immune cells interacting with CD72 on B cells or plasma cells promotes B cell activation and differentiation, crucial for humoral immunity.
T Cell Modulation:
- CD160-TNFRSF14-T CD8+: CD160 (on T cells) binding to TNFRSF14 (HVEM) can modulate T cell activity, playing roles in both co-stimulation and co-inhibition, contributing to T cell fate decisions.
- Prostaglandin E2_byPTGES3-PTGER4-T CD8+: Prostaglandin E2 (PGE2) signaling via its receptor PTGER4 (EP4) on T cells can have diverse immunomodulatory effects, often dampening T cell responses, which might be involved in maintaining immune tolerance in normal tissue. GeneCards: PTGER4
Tumor-Associated Cell-Cell Interactions
The tumor microenvironment (TME) is characterized by distinct interaction patterns that often contribute to immune evasion, tumor progression, and T cell dysfunction.
Immune Checkpoint & T Cell Exhaustion Pathways:
- NECTIN2-TIGIT-Ent.Epi (Dip)|T CD4+: This is a critical immune checkpoint pathway. TIGIT (T cell immunoreceptor with Ig and ITIM domains) on T cells (here, CD4+) binds to NECTIN2 on target cells (here, diploid Intestinal Epithelial cells, potentially tumor cells or cells in their vicinity). TIGIT engagement leads to T cell exhaustion and suppresses anti-tumor immunity. UniProt: TIGIT
- VSIR-HLA-E-T CD4+|B cell: VSIR (VISTA) is another immune checkpoint molecule. Its interaction with HLA-E on B cells could contribute to immunosuppression within the TME.
- BTLA-TNFRSF14-T CD4+|T CD4+: BTLA (B and T lymphocyte attenuator) is an inhibitory receptor on T cells that binds to TNFRSF14 (HVEM). This interaction contributes to T cell suppression and exhaustion, often observed in chronic infections and cancer.
Tumor-Associated Adhesion & Immune Evasion:
- CEACAM5-CD8A-Ent.Epi (Dip)|T CD8+: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a known tumor marker frequently overexpressed in colorectal cancer. Its interaction with CD8A on cytotoxic T cells suggests a direct impact on anti-tumor immune responses, potentially contributing to T cell dysfunction or evasion. GeneCards: CEACAM5
- SIRPG-CD47-T CD4+|B cell: CD47, often overexpressed by cancer cells and sometimes immune cells, acts as a "don't eat me" signal by binding to SIRPα (encoded by SIRPG) on phagocytes or other immune cells, facilitating immune evasion. UniProt: CD47
- CD55-ADGRE5-Ent.Epi (Dip)|T CD4+: CD55 (DAF) and ADGRE5 (CD97) are involved in cell adhesion and immune regulation, and their increased interaction in tumor settings might contribute to altered cell migration or immune suppression.
Altered T Cell & Plasma Cell Communication:
- CD320-JAML-Plasma|T CD4+ and CD320-JAML-Plasma|T CD8+: Interactions between CD320 (transcobalamin receptor) on plasma cells and JAML (Junctional Adhesion Molecule Like) on T cells may modulate leukocyte adhesion, transmigration, and potentially facilitate plasma cell accumulation or function in the TME.
- CD40LG-CD40-T CD4+|Plasma: CD40L (CD40LG) on T cells interacting with CD40 on plasma cells is essential for humoral immunity and T cell-dependent antibody production. Its presence in the TME could indicate ongoing or dysregulated adaptive immune responses.
Role of Diploid Intestinal Epithelial Cells
The prevalence of interactions involving Intestinal Epithelial cell (Dip) is noteworthy. As Intestinal Epithelial cells are identified as the tumor origin cell type, these diploid epithelial cells could represent:
- Normal epithelial cells within the tumor microenvironment.
- Diploid tumor cell populations or pre-malignant cells, which may interact differently from aneuploid tumor cells (though interactions with aneuploid cells are not explicitly shown here).
The specific engagement of these diploid epithelial cells in immune checkpoint pathways like NECTIN2-TIGIT and tumor-associated signaling like CEACAM5-CD8A suggests their critical role in shaping the local immune response in the context of malignancy.
Clinical or Translational Implications
The differential CCI patterns between normal and tumor conditions offer crucial insights for therapeutic development, particularly in colorectal cancer.
- Immune Checkpoint Targeting: The strong emergence of NECTIN2-TIGIT and BTLA-TNFRSF14 interactions in tumor samples highlights these as promising targets for immune checkpoint blockade therapies to reactivate exhausted T cells and enhance anti-tumor immunity.
- Targeting Immune Evasion Pathways: The SIRPG-CD47 interaction in the tumor context suggests that therapies aimed at blocking the "don't eat me" signal could be beneficial in promoting phagocytosis of tumor cells or modulating T cell behavior.
- Addressing Tumor-Associated Antigens: The interaction involving CEACAM5 and CD8 T cells in the tumor environment underscores the potential of targeting tumor-associated antigens or pathways that modulate T cell recognition and function.
- Understanding TME Plasticity: Characterizing these shifts in CCI profiles provides a comprehensive view of how intercellular communication is rewired in cancer. This understanding can inform strategies to reprogram the tumor microenvironment to be more hospitable to anti-tumor immune responses, potentially combining CCI-targeting agents with existing treatments.
16. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies condition-specific surfaceome markers for Intestinal Epithelial cells. The provided dot plot visualizes the expression of up to 50 surface markers across various individual samples, categorized by their inferred ploidy status and origin (tumor vs. normal-like). The goal is to highlight surface proteins that are differentially expressed, particularly in tumor-origin Intestinal Epithelial cells, compared to normal or diploid counterparts.
Visual Summary
The dot plot effectively displays the mean expression (color intensity) and the fraction of cells expressing a gene (dot size) for each marker across different samples.
- Distinct Clustering by Sample Type: The samples on the Y-axis clearly separate into two main groups. The majority of samples, prefixed with "Diploid" (e.g., "Diploid B_cac6", "Diploid T_cac11"), primarily show low to no expression for most markers. In contrast, a distinct cluster of samples at the bottom, labeled "T_cac3", "T_cac1", and "T_cac8", exhibit strong and widespread expression of numerous markers.
- Tumor-Specific Upregulation: The "T_cac3", "T_cac1", and "T_cac8" samples, which are likely derived from tumor tissue and represent transformed Intestinal Epithelial cells (potentially aneuploid given the absence of the "Diploid" prefix), show robust upregulation of a broad panel of surfaceome genes. For these samples, the dots are large and dark red, indicating both a high fraction of cells expressing these genes and high mean expression levels.
- Key Upregulated Markers in Tumor Cells: A substantial set of markers, including MUC4, CD63, CEACAM5, CEACAM6, ITM2B, BSG, AREG, LMAN2, TMEM219, FCGRT, TSPAN3, BACE2, CD46, RNF43, TMEM123, RPN1, CDH1, HM13, LAMP1, APLP2, TM9SF2, DSG2, PLPP2, PTTG1IP, GPRC5A, SLC39A4, NECTIN2, CD44, and DPEP1, are highly expressed in the tumor-associated samples ("T_cac3", "T_cac1", "T_cac8") but largely absent or expressed at very low levels in the "Diploid" samples.
- Minimal Expression in Diploid Samples: The "Diploid" samples generally show very little to no expression of these identified markers, with some exceptions of sporadic, low-level expression for a few markers in certain samples. This reinforces the specificity of these markers to the transformed state.
- Sample Cell Counts: The bar charts on the right indicate the number of cells analyzed per sample group, showing substantial cell numbers for most groups, supporting the robustness of the observed expression patterns. For instance, "T_cac1" has 519 cells and "T_cac3" has 334 cells, indicating representative populations.
Biological Interpretation
This analysis successfully identifies a set of highly specific surfaceome markers that differentiate tumor-origin Intestinal Epithelial cells from their normal or diploid counterparts. The observed differential expression reflects profound molecular changes occurring at the cell surface during colorectal tumorigenesis.
- Signatures of Transformation: The significant upregulation of numerous surface proteins in the "T_cac" samples provides a molecular signature of tumor cell transformation. Many of these genes are known to play crucial roles in cancer biology.
- Oncogenic Signaling and Adhesion: Markers like MUC4 [1], CEACAM5 (CEA), CEACAM6 [2, 3], BSG (CD147) [4], and AREG (Amphiregulin) [5] are frequently overexpressed in various cancers, including colorectal cancer. They are implicated in critical processes such as cell proliferation, invasion, metastasis, cell adhesion, and immune evasion. The presence of CD44, a known marker for cancer stem cells and tumor progression [6], further supports the identification of a tumor cell population.
- Altered Cell Surface Glycosylation/Structure: The broad changes in surface protein expression, including mucins (MUC4), carcinoembryonic antigens (CEACAMs), and adhesion molecules, indicate a dramatically altered cell surface landscape in tumor cells, affecting cell-cell interactions, microenvironment sensing, and immune recognition.
- Heterogeneity within Tumor Microenvironment: While the "T_cac" samples clearly represent the dominant tumor signature, the "Diploid T_cac" samples (e.g., Diploid T_cac11, Diploid T_cac2) show some low-level or sporadic expression of a few markers. These might represent diploid Intestinal Epithelial cells within the tumor microenvironment that are undergoing reactive changes or early stages of transformation, or are responding to tumor-secreted factors.
Clinical or Translational Implications
The identification of these surfaceome markers for Intestinal Epithelial cells in the context of tumor vs. normal conditions has significant clinical and translational potential.
Diagnostic and Prognostic Biomarkers:
- The highly specific upregulation of markers such as MUC4, CEACAM5, CEACAM6, BSG, AREG, and CD44 on tumor-origin Intestinal Epithelial cells makes them excellent candidates for diagnostic biomarkers for colorectal cancer. Their surface localization allows for detection through various methods, including immunohistochemistry on tissue biopsies, flow cytometry on dissociated cells, or even non-invasive approaches such as liquid biopsies (e.g., detection of circulating tumor cells or exosomes) [2, 3, 6].
- Differential expression levels of these markers could also serve as prognostic indicators, potentially correlating with disease aggressiveness, stage, or response to therapy.
Therapeutic Targets:
- Given their presence on the cell surface, these identified proteins are highly attractive as therapeutic targets for precision oncology.
- For example, CEACAM5 has already been extensively studied as a target for antibody-drug conjugates (ADCs) in clinical trials for various cancers, including colorectal cancer [10]. Similarly, BSG (CD147) and CD44 are actively investigated for targeted therapies due to their roles in tumor progression and stemness [11, 12].
- These markers could also be utilized for developing CAR T-cell therapies or bispecific antibodies to specifically target and eliminate tumor-origin Intestinal Epithelial cells, while sparing normal tissues.
Experimental Validation:
- Further experimental validation, such as detailed immunohistochemical analysis on a larger cohort of human colon normal and tumor tissues, or functional studies using in vitro and in vivo models, would be crucial to confirm their utility as robust biomarkers or therapeutic targets.
---
References:
- MUC4 in cancer: PubMed search for "MUC4 colorectal cancer" https://pubmed.ncbi.nlm.nih.gov/?term=MUC4+colorectal+cancer
- CEACAM5 (CEA): GeneCards entry for CEACAM5 https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM5
- CEACAM6: GeneCards entry for CEACAM6 https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM6
- BSG (CD147): GeneCards entry for BSG https://www.genecards.org/cgi-bin/carddisp.pl?gene=BSG
- AREG (Amphiregulin): GeneCards entry for AREG https://www.genecards.org/cgi-bin/carddisp.pl?gene=AREG
- CD44: GeneCards entry for CD44 https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD44
- CDH1 (E-cadherin) in cancer: PubMed search for "E-cadherin colorectal cancer" https://pubmed.ncbi.nlm.nih.gov/?term=E-cadherin+colorectal+cancer
- DPEP1 in cancer: PubMed search for "DPEP1 cancer" https://pubmed.ncbi.nlm.nih.gov/?term=DPEP1+cancer
- CD63 in cancer: PubMed search for "CD63 cancer" https://pubmed.ncbi.nlm.nih.gov/?term=CD63+cancer
- CEACAM5-targeting therapies: PubMed search for "CEACAM5 antibody drug conjugate" https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM5+antibody+drug+conjugate
- BSG/CD147 targeting: PubMed search for "CD147 targeting cancer" https://pubmed.ncbi.nlm.nih.gov/?term=CD147+targeting+cancer
- CD44 targeting: PubMed search for "CD44 targeting cancer" https://pubmed.ncbi.nlm.nih.gov/?term=CD44+targeting+cancer
17. Cell-Type Specific Surfaceome Markers for Macrophage Subtypes in Human Colon
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify condition-specific surfaceome markers for macrophages. The provided visualization is a dot plot displaying cell-type specific surfaceome markers across various cell subsets found in human colon tissue, including Macrophage (M1) and Macrophage (M2B) subtypes. While the initial query focused on "condition-specific markers," the output visualizes markers that are highly specific to individual cell types (or subtypes) within the dataset, allowing for differentiation between these populations. The selection was restricted to surfaceome markers, which are particularly valuable for cell sorting, imaging, and therapeutic targeting.
Visual Summary
The dot plot effectively illustrates the expression patterns of selected surfaceome genes across different cell types and subsets, as identified by celltype_subset.
- Dot Size: Represents the fraction of cells within each group (row) that express the given gene (column). Larger dots indicate higher prevalence of expression.
- Dot Color Intensity: Represents the mean expression level of the gene in the expressing cells within that group. Darker red indicates higher mean expression.
- Red Boxes: Highlight genes that are most specifically expressed and enriched within a particular cell type or subtype, indicating their potential as unique markers.
- Cell Counts: The bar plot on the right displays the total number of cells contributing to each celltype_subset, indicating the sample size for each group (e.g., Macrophage (M1) has 228 cells, Macrophage (M2B) has 392 cells).
Key observations for Macrophages:
- Macrophage (M1) Specificity: A distinct set of markers, including IFNGR1, IFNGR2, SOCS3, MARCKSL1, CYBA, and FCGR3A, show high expression and high prevalence specifically within Macrophage (M1) cells, as indicated by the prominent red box. These markers exhibit very low or no expression in most other cell types, suggesting strong specificity.
- Macrophage (M2B) Specificity: For Macrophage (M2B), markers like KLRD1, GPX2, JCHAIN, and MZB1 are notably enriched. While KLRD1 and GPX2 appear more specific to M2B within the macrophage lineage, JCHAIN and MZB1 are also very strongly expressed in Plasma cells, suggesting a shared expression profile or distinct functional overlap for these genes.
Biological Interpretation
The identified surfaceome markers provide significant biological insights into the distinct characteristics and potential functions of macrophage subtypes in the human colon, which can be critical in both normal physiology and disease states like colon cancer (given the conditions: normal, tumor in the data context).
- Macrophage (M1) Polarization Markers:
- IFNGR1 (Interferon Gamma Receptor 1) and IFNGR2 (Interferon Gamma Receptor 2): The high and specific expression of these receptor chains in M1 macrophages strongly indicates their responsiveness to interferon-gamma (IFN-$\gamma$). IFN-$\gamma$ is a hallmark cytokine for M1 polarization, activating pro-inflammatory and anti-tumorigenic responses [PubMed Search: IFNGR1 IFNGR2 macrophage M1 polarization].
- CYBA (Cytochrome B-245 Alpha Chain): This gene encodes a subunit of the NADPH oxidase complex (NOX2), which is crucial for the production of reactive oxygen species (ROS) in M1 macrophages, essential for pathogen killing and inflammatory responses [UniProt: P13498 (CYBA)].
- FCGR3A (Fc Gamma Receptor IIIA, CD16): An Fc receptor primarily expressed on NK cells, monocytes, and macrophages. Its presence in M1 macrophages is consistent with their role in antibody-dependent cellular cytotoxicity (ADCC) and immune complex clearance, characteristic of pro-inflammatory macrophages.
- SOCS3 (Suppressor of Cytokine Signaling 3) and MARCKSL1 (MARCKS-Like Protein 1): SOCS3 is an intracellular protein known to regulate cytokine signaling pathways, often induced by inflammation, while MARCKSL1 is involved in cell adhesion, migration, and membrane dynamics. Their specific enrichment in M1 macrophages highlights the complex signaling and cellular processes underpinning M1 activation.
- Macrophage (M2B) Polarization Markers:
- KLRD1 (Killer Cell Lectin Like Receptor D1, CD94): While also found on NK cells, its high expression in M2B macrophages suggests a potential role in immune recognition or modulation, possibly bridging innate and adaptive immunity.
- GPX2 (Glutathione Peroxidase 2): An antioxidant enzyme involved in protecting cells from oxidative damage. Its presence in M2B macrophages could reflect their role in resolving inflammation and tissue repair, often associated with M2 phenotypes, but M2B macrophages are also known for their pro-inflammatory characteristics under specific stimuli.
- JCHAIN (Joining Chain of Immunoglobulin M and A) and MZB1 (Myeloid B-cell Differentiation Antigen 1): The distinct expression of JCHAIN and MZB1 in M2B macrophages, genes typically associated with B cells and plasma cells (especially for immunoglobulin synthesis and secretion), is an intriguing finding. This could suggest:
- A unique sub-polarization state of M2B macrophages with an unusual secretory or immune complex processing capacity.
- Potential interaction or phenotypic crosstalk with B/Plasma cells in the colon microenvironment.
- The M2B subtype is less uniformly defined than other M2 subtypes, and its characteristics can vary depending on context. This observation warrants further investigation to understand its specific functional implications.
Clinical or Translational Implications
The identification of specific surfaceome markers for macrophage subtypes holds significant clinical and translational value, particularly in the context of colon diseases such as inflammatory bowel disease or colorectal cancer (given tissue: Colon and conditions: normal, tumor).
- Diagnostic and Prognostic Biomarkers: These distinct surface markers can serve as reliable tools for precisely identifying and quantifying M1 and M2B macrophage populations in patient biopsies or circulating cells using techniques like flow cytometry or immunohistochemistry. Changes in the balance or specific activation states of M1/M2B macrophages could act as biomarkers for disease progression, therapeutic response, or prognosis in colon cancer.
- Targeted Therapies: As surfaceome proteins, these markers represent attractive therapeutic targets. For instance:
- Targeting IFNGR1/2 on M1 macrophages could modulate their pro-inflammatory activity.
- Understanding the role of JCHAIN/MZB1 in M2B macrophages could reveal novel pathways for intervention, especially if M2B cells contribute to a pro-tumorigenic or immunosuppressive microenvironment in colon cancer. Modulating the functions of these macrophage subsets could lead to new immunotherapeutic strategies or approaches to dampen detrimental inflammation.
- Experimental Validation and Functional Studies: These markers provide clear targets for *ex vivo* sorting of specific macrophage subtypes for further functional studies, such as investigating their cytokine profiles, phagocytic activity, or interactions with other immune and stromal cells in normal versus tumor conditions. This precision will enable a deeper understanding of macrophage plasticity and their roles in health and disease.
18. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies and visualizes condition-specific surfaceome markers in Fibroblasts, comparing 'normal' and 'tumor' conditions within the colon tissue. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing a gene (dot size) for selected surface markers across different fibroblast sub-clusters (B_cac14, T_cac1, T_cac2, T_cac3) in both normal and tumor contexts. The "surfaceome_only" parameter ensures that only cell surface proteins, which are often key players in cell-cell interactions and amenable to therapeutic targeting, are presented.
Visual Summary
The dot plot clearly differentiates two major groups of fibroblast-expressed surface markers: those enriched in the 'normal' condition (left red box) and those enriched in the 'tumor' condition (right red box).
- Normal Condition Markers: A set of genes, including PLPP3, ABCA8, CD9, LMBRD1, SCARA5, ATP1A1, GPNMB, TGFBR3, CD34, RNF13, ABCA6, and PI16, shows high expression and prevalence primarily within the B_cac14 fibroblast cluster under normal conditions. These markers are largely absent or expressed at very low levels in the tumor condition.
- Tumor Condition Markers: A distinct set of genes, such as F2R, PTTG1IP, ANTXR1, CDH11, ITGA1, MMP14, CD55, ITGAV, TMEM123, NECTIN2, TMEM30A, ICAM1, LTBR, FAT1, IFNGR2, OSMR, and CD82, exhibits strong expression in the tumor condition, particularly within the T_cac1, T_cac2, and T_cac3 fibroblast clusters. These markers are minimally expressed in the normal condition.
- Fibroblast Heterogeneity: The plot reveals heterogeneity among fibroblasts. The B_cac14 cluster (41 cells) is predominantly associated with normal tissue. The T_cac1 (77 cells), T_cac2 (189 cells), and T_cac3 (102 cells) clusters are primarily associated with the tumor microenvironment, with T_cac1 showing the most prominent upregulation of tumor-associated markers. T_cac2 and T_cac3 display similar but generally less pronounced patterns of tumor marker expression, suggesting distinct states or activation levels of cancer-associated fibroblasts (CAFs).
Biological Interpretation
The distinct sets of surfaceome markers identify clear transcriptional shifts in fibroblasts between normal colon tissue and the tumor microenvironment. This highlights the dynamic adaptation and functional specialization of fibroblasts in response to oncogenic stimuli.
Normal Fibroblast Signatures (B_cac14 cluster)
Fibroblasts in normal colon tissue (represented by the B_cac14 cluster) express markers that suggest roles in tissue homeostasis and basic cellular functions:
- Lipid Metabolism/Transport: Genes like PLPP3, ABCA8, and ABCA6 are involved in lipid phosphate metabolism and cholesterol efflux GeneCards: PLPP3, GeneCards: ABCA8, potentially reflecting metabolic steady-state or specialized lipid handling in normal stromal cells.
- Cell Adhesion and Signaling: CD9 (a tetraspanin) and SCARA5 (scavenger receptor) play roles in cell adhesion, migration, and signaling. SCARA5 is also implicated as a tumor suppressor in some contexts, consistent with a role in maintaining tissue integrity in normal physiology GeneCards: SCARA5.
- Modulation of Growth Factor Signaling: TGFBR3, a co-receptor for TGF-beta, can modulate TGF-beta signaling, which is crucial for tissue repair and maintenance.
Tumor-Associated Fibroblast Signatures (T_cac1, T_cac2, T_cac3 clusters)
Fibroblasts in the tumor microenvironment (CAFs) exhibit a dramatic shift in their surfaceome, acquiring markers that promote tumor growth, invasion, and immune evasion:
- ECM Remodeling and Invasion: MMP14 (MT1-MMP) is a critical membrane-bound matrix metalloproteinase that degrades the extracellular matrix, facilitating tumor cell invasion and metastasis GeneCards: MMP14. Upregulation of integrins like ITGA1 and ITGAV further highlights enhanced cell-ECM interactions and migratory potential crucial for CAF function in remodeling the tumor microenvironment GeneCards: ITGAV.
- Pro-tumorigenic Signaling: F2R (PAR1), the thrombin receptor, is activated by proteases in the tumor microenvironment and can promote tumor growth, angiogenesis, and inflammation PubMed: PAR1 cancer. ANTXR1 (TEM8) is linked to angiogenesis and tumor growth GeneCards: ANTXR1. OSMR, the Oncostatin M receptor, signals for inflammation and fibrosis, promoting cancer progression in stromal cells GeneCards: OSMR.
- Cell Adhesion and Communication: CDH11 (Cadherin 11) mediates cell-cell adhesion and is often associated with mesenchymal cell differentiation and cancer progression, contributing to tumor invasion GeneCards: CDH11. NECTIN2 and ICAM1 are also adhesion molecules that facilitate interactions with other cells, including immune cells, potentially modulating immune responses within the tumor GeneCards: NECTIN2, GeneCards: ICAM1.
- Immune Evasion: CD55 protects cells from complement-mediated lysis, and its overexpression in tumor cells and stromal cells can contribute to immune evasion GeneCards: CD55.
- CAF Heterogeneity: The strong expression of these pro-tumorigenic markers in the T_cac1 cluster suggests it represents a highly activated, "pro-tumorigenic" CAF subtype. The T_cac2 and T_cac3 clusters, while also tumor-associated, show varying expression levels and fractions of expressing cells for some markers, indicating functional diversity and potential sub-specialization of CAFs within the colon tumor microenvironment. For example, FAT1 and IFNGR2 show differential patterns across these tumor-associated clusters.
Clinical or Translational Implications
The identified condition-specific surfaceome markers in fibroblasts offer significant clinical and translational potential, particularly for colon cancer:
- Biomarker Discovery: Genes like MMP14, ANTXR1, CDH11, ITGAV, F2R, and OSMR are highly upregulated and specific to tumor-associated fibroblasts. These could serve as valuable biomarkers for diagnosing colon cancer, assessing disease progression, or distinguishing between normal and tumor tissue components. Given their surface localization, they are prime candidates for detection via immunohistochemistry or flow cytometry in clinical samples.
- Therapeutic Targets: The surface accessibility of these markers makes them attractive therapeutic targets. For instance, inhibiting MMP14 could reduce ECM degradation and tumor invasion. Targeting ANTXR1 or F2R could disrupt pro-angiogenic or pro-tumorigenic signaling pathways within the tumor stroma. Developing antibodies or small molecules against these specific CAF surface proteins could offer novel strategies for anti-cancer therapy, potentially sensitizing tumors to existing treatments or reducing metastasis.
- Understanding CAF Function and Heterogeneity: The identification of distinct CAF subtypes (T_cac1, T_cac2, T_cac3) based on their surfaceome profiles underscores the need for a nuanced understanding of CAF biology. This heterogeneity might explain varying responses to therapies and suggests that targeting specific CAF subsets, rather than all fibroblasts, could lead to more effective and less toxic treatments. Further research into the unique functional contributions of each CAF subtype could refine therapeutic approaches.
- Prognostic Indicators: The expression patterns of these markers could also correlate with patient prognosis, potentially informing personalized treatment strategies. For example, high expression of highly activated CAF markers might indicate a more aggressive tumor phenotype.
19. Condition-Specific Surfaceome Markers in CD4+ T cells
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify surfaceome markers that are differentially expressed between CD4+ T cells derived from normal colon tissue and those from tumor tissue. The plot_markers_and_expression_dot tool was used to visualize the mean expression and fraction of cells expressing these markers across different samples, grouped by condition. The focus on surfaceome markers is particularly relevant for identifying potential therapeutic targets or biomarkers accessible via cell surface.
Visual Summary
The dot plot effectively visualizes the expression patterns of 30 distinct surfaceome markers across various samples of CD4+ T cells, segregated by their origin (normal vs. tumor colon tissue).
- Clustering by Condition: A clear hierarchical clustering is evident on the y-axis, grouping samples predominantly from 'normal' conditions together and 'tumor' conditions together. This indicates that the CD4+ T cell populations in these two conditions possess distinct surface proteomic profiles.
- Normal-Specific Markers: The upper cluster of samples, primarily from 'normal' conditions (e.g., B_cac14, B_cac11, B_cac15), exhibits high and prevalent expression (large, dark red dots) of genes such as CCR7, AREG, SELPLG, CCRG, RNF167, and CD82. These markers are largely absent or expressed at very low levels in the tumor samples.
- Tumor-Specific Markers: Conversely, the lower cluster of samples, predominantly from 'tumor' conditions (e.g., T_cac16, T_cac9, T_cac6), shows high and prevalent expression of a distinct set of markers. These include CTLA4, LDLRAD4, SLAMF1, TNFRSF4 (OX40), TNFRSF18 (GITR), ITGAE (CD103), FAS (TNFRSF6), HLA-DPA1, TNFRSF25, CXCR6, CD63, CD58, SPN, IL2RB, and ENTPD1 (CD39). These markers are generally lowly expressed or absent in the normal samples.
- Expression and Prevalence: The color intensity of the dots indicates the mean expression level, with darker reds signifying higher expression. The size of the dots represents the fraction of cells within a given sample group expressing the gene. Both metrics clearly show strong differential patterns between the normal and tumor conditions.
- Sample Representation: The bar chart on the right indicates the number of cells contributing to each sample group, ranging from 52 to 2910 cells. This indicates that the observed patterns are robustly supported by a sufficient number of cells in most sample groups.
Biological Interpretation
The distinct surfaceome profiles of CD4+ T cells in normal versus tumor colon tissue provide significant biological insights into their functional states and roles within their respective microenvironments.
Normal Colon CD4+ T cells
- CCR7: This chemokine receptor is critical for T cell homing to secondary lymphoid organs and plays a role in central memory T cell function. Its high expression suggests a population of circulating or resident T cells capable of migration and maintaining immune surveillance in healthy tissue. PubMed: CCR7 and T cell homing
- AREG (Amphiregulin): A ligand for EGFR, AREG is involved in tissue repair and epithelial proliferation. Its expression in normal CD4+ T cells might contribute to maintaining intestinal epithelial integrity or modulating local inflammation. GeneCards: AREG
- SELPLG (CD162, PSGL-1): This glycoprotein mediates leukocyte rolling and adhesion, facilitating immune cell extravasation into tissues. Its presence supports the normal migratory capacity of T cells. GeneCards: SELPLG
- Other markers like RNF167 and CD82 suggest roles in general T cell function and intercellular interactions within a healthy immune context.
- Tumor Colon CD4+ T cells: The markers observed in tumor-associated CD4+ T cells point towards an activated, often exhausted or regulatory, and tissue-adapted phenotype within the immunosuppressive tumor microenvironment (TME).
Immune Checkpoints/Co-regulatory Molecules
- CTLA4: A well-known inhibitory receptor crucial for dampening T cell responses. Its upregulation is characteristic of regulatory T cells (Tregs) and activated T cells that are undergoing exhaustion, promoting immune evasion in cancer. UniProt: CTLA4
- TNFRSF4 (OX40) and TNFRSF18 (GITR): These are co-stimulatory receptors that promote T cell activation and survival. While their expression indicates T cell activation, in the chronic inflammatory context of cancer, sustained signaling via these receptors can also contribute to T cell exhaustion or the maintenance of regulatory populations. GeneCards: TNFRSF4, GeneCards: TNFRSF18
- FAS (TNFRSF6): A death receptor, its increased expression can render T cells susceptible to apoptosis, which is a mechanism of immune evasion employed by tumors. GeneCards: FAS
Adhesion/Migration/Metabolic Markers
- ITGAE (CD103): This integrin is often expressed on tissue-resident memory T cells (TRMs) and intraepithelial lymphocytes (IELs) in the gut. In the tumor context, CD103+ CD4+ T cells can have both effector and regulatory functions, including contributing to an immunosuppressive environment. GeneCards: ITGAE
- CXCR6: A chemokine receptor involved in T cell trafficking and tissue retention. Its upregulation suggests specific localization or migratory patterns of CD4+ T cells within the TME. GeneCards: CXCR6
- ENTPD1 (CD39): This ectonucleotidase is involved in ATP hydrolysis, producing adenosine, which is a potent immunosuppressive molecule in the TME. CD39 expression is a hallmark of immunosuppressive Tregs and exhausted T cells. GeneCards: ENTPD1
- HLA-DPA1: Part of the MHC class II complex. While primarily expressed by professional antigen-presenting cells, activated T cells, including some CD4+ subsets or Tregs, can express MHC class II, potentially indicating an altered activation state or even antigen presentation capabilities in the TME.
Clinical or Translational Implications
The identification of condition-specific surfaceome markers in CD4+ T cells has several important clinical and translational implications for colon cancer.
- Biomarker Discovery: The distinct sets of markers can serve as potential diagnostic or prognostic biomarkers. For instance, a high ratio of tumor-specific markers (e.g., CTLA4, ENTPD1) to normal-specific markers (e.g., CCR7) in CD4+ T cells isolated from tumor biopsies or circulating cells could indicate disease presence or progression.
- Therapeutic Targets: Several identified tumor-specific markers are already targets or candidates for immunotherapies:
- CTLA4: A validated immune checkpoint target (e.g., ipilimumab) for various cancers. Its upregulation on tumor-infiltrating CD4+ T cells in colon cancer suggests its continued relevance as a therapeutic target to unleash anti-tumor immunity.
- TNFRSF4 (OX40) and TNFRSF18 (GITR): These co-stimulatory receptors are targets for agonistic antibodies aimed at enhancing T cell responses. Their expression patterns warrant investigation into whether OX40/GITR agonists could selectively boost beneficial CD4+ T cell subsets in the colon TME without exacerbating immunosuppression.
- ENTPD1 (CD39): Inhibitors of CD39 are being developed to counteract adenosine-mediated immunosuppression. The prominent expression of CD39 on tumor-associated CD4+ T cells positions it as a promising target to reprogram the immunosuppressive TME.
- Understanding TME Dynamics: These markers provide a molecular signature of CD4+ T cell adaptation to the tumor microenvironment, highlighting shifts towards immunosuppression, exhaustion, and altered migratory capacities. This understanding can guide the development of combination therapies that address multiple facets of immune dysfunction.
- Experimental Validation: The identified surfaceome markers are excellent candidates for further experimental validation using techniques like flow cytometry or immunohistochemistry on patient samples to confirm protein expression patterns. Functional studies *in vitro* and *in vivo* could then assess the impact of modulating these targets on CD4+ T cell effector functions and anti-tumor immunity in colon cancer models.
20. Intestinal Epithelial Cell Cycle Deregulation in Colon Tumorigenesis
[Analysis Visualization Results]...
Analysis Overview
This analysis investigated the expression levels of 24 selected cell cycle pathway-related genes in Intestinal Epithelial cells, comparing normal colon tissue to tumor tissue. The goal was to identify statistically significant differences in gene expression that might contribute to the disease state. The plot_box_for_gene_expression_with_signif_difference tool was used, displaying the distribution of gene expression per sample as box plots with individual data points (stripplot) and highlighting significant differences with p-values.
Visual Summary
The box plots reveal a consistent pattern of upregulation for the majority of the analyzed cell cycle-related genes in Intestinal Epithelial cells from tumor samples compared to normal samples. Key observations include:
Significant Upregulation in Tumor Cells (p ≤ 0.05 or p ≤ 0.01):
- Cell Cycle Progression & Regulation: ANAPC11, ANAPC5 (components of the Anaphase Promoting Complex/Cyclosome, APC/C), CCND1 (Cyclin D1), CDK4 (Cyclin-dependent kinase 4), MYC (proto-oncogene), RAD21 (cohesin complex subunit), RBX1 (SCF complex component).
- Epigenetic Modifiers: HDAC2 (Histone deacetylase 2).
- DNA Repair/Genome Stability: PRKDC (DNA-dependent protein kinase catalytic subunit).
- Signal Transduction/Cell Survival (14-3-3 Family): YWHAB, YWHAE, YWHAH, YWHAP, YWHAZ.
Tendency Towards Upregulation in Tumor Cells (p < 0.1):
- HDAC1 (p = 0.06), SKP1 (p = 0.07). These genes show a similar trend, nearing statistical significance.
Tendency Towards Downregulation in Tumor Cells (p < 0.1):
- GADD45B (p = 0.08) shows a trend towards lower expression in tumor cells.
- Expression Distribution: For most upregulated genes, the box plots for tumor samples show higher median expression values and often a wider range, indicating increased and more variable expression compared to normal samples. The individual sample means (black dots) demonstrate the observed variability.
Biological Interpretation
The findings strongly suggest a profound dysregulation of cell cycle control mechanisms in Intestinal Epithelial cells during colon tumorigenesis. The observed gene expression changes are consistent with hallmarks of cancer, particularly sustained proliferative signaling and evasion of growth suppressors.
- Accelerated Cell Cycle Progression: The significant upregulation of core cell cycle machinery components like CCND1 (Cyclin D1) and CDK4 drives the G1-S phase transition, promoting cell division. Similarly, the increased expression of ANAPC11 and ANAPC5, components of the APC/C, which controls anaphase and mitotic exit by ubiquitinating cell cycle proteins, suggests an actively cycling and potentially hyper-proliferative state. The upregulation of RAD21, a cohesin subunit, also points to active chromosome segregation during rapid cell division.
- Oncogenic Drive: The prominent upregulation of the proto-oncogene MYC is a critical finding. MYC is a master regulator of cell proliferation, growth, and metabolism. Its overexpression is a common event in many cancers, driving uncontrolled cell division and contributing to malignant transformation.
- Epigenetic Reprogramming: The increased expression of HDAC1 and HDAC2 indicates altered epigenetic regulation in tumor cells. Histone deacetylases modify chromatin structure, typically leading to transcriptional repression. Their upregulation can contribute to silencing tumor suppressor genes or promoting oncogenic pathways, thereby supporting unchecked proliferation [UniProt: P23770 (HDAC1), P84122 (HDAC2)].
- DNA Repair and Genomic Instability: Upregulation of PRKDC (DNA-PKcs), a key enzyme in non-homologous end joining (NHEJ) DNA repair, could indicate an increased need for DNA damage repair in rapidly dividing tumor cells. While DNA repair is crucial, an enhanced, potentially error-prone, repair capacity can allow damaged cells to survive and accumulate further mutations, contributing to genomic instability characteristic of cancer.
- Dysregulated Protein Degradation: Upregulation of RBX1 and SKP1, components of the SCF E3 ubiquitin ligase complexes, suggests altered proteasomal degradation of cell cycle regulators. SCF complexes target proteins for degradation, promoting cell cycle progression. Their overexpression can lead to the inappropriate degradation of cell cycle inhibitors, further driving proliferation.
- Altered Signal Transduction (14-3-3 Proteins): The consistent upregulation of multiple 14-3-3 family proteins (YWHAB, YWHAE, YWHAH, YWHAQ, YWHAZ) is notable. These proteins act as crucial signaling adaptors, modulating the activity of a wide array of proteins involved in cell cycle control, apoptosis, signal transduction, and cell survival. Their increased expression can collectively contribute to an environment favoring cell growth, survival, and evasion of apoptotic signals in cancer cells [PubMed Search: 14-3-3 proteins cancer role].
- Loss of Growth Arrest Signals: The trend of GADD45B downregulation in tumor cells is significant. GADD45 proteins are typically induced by stress and play roles in cell cycle arrest, DNA repair, and apoptosis. Reduced GADD45B expression could impair crucial cell cycle checkpoints, allowing damaged or abnormal cells to proliferate without proper control [GeneCards: GADD45B].
Clinical or Translational Implications
The pervasive upregulation of cell cycle-promoting genes and downregulation of growth arrest genes in Intestinal Epithelial cells of colon tumors highlights critical pathways that can be exploited for therapeutic intervention.
- Therapeutic Targets: Genes like CDK4, CCND1, MYC, and HDAC1/2 are well-established oncogenic drivers and represent promising therapeutic targets. CDK4/6 inhibitors are already used in certain cancers, and their potential in colorectal cancer warrants further investigation. Similarly, HDAC inhibitors are a class of anti-cancer drugs that could be relevant here [PubMed Search: CDK4/6 inhibitors colon cancer]. Targeting the upregulated APC/C components or the 14-3-3 proteins could also be explored as novel strategies.
- Biomarkers: The differential expression patterns of these genes could serve as valuable biomarkers for diagnosing colon cancer, assessing tumor aggressiveness, or predicting response to therapy. For example, high expression of MYC or specific HDACs might indicate a more aggressive tumor phenotype.
- Understanding Pathogenesis: These findings provide a deeper understanding of the molecular mechanisms underlying colon tumorigenesis, specifically the central role of deregulated cell cycle progression in Intestinal Epithelial cells, the presumed cells of origin for colon cancer. This mechanistic insight can guide the development of more effective and targeted therapies.
21. Intestinal Epithelial Cell Gene Ontology (GSA) Analysis: Ploidy and Tumor-Associated Pathway Shifts
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the biological pathways enriched in Intestinal Epithelial cells under two different comparison contexts using Gene Set Analysis (GSA), specifically Gene Ontology (GO) enrichment. The results are presented as bar plots, showing the -log(p-val) and -log(q-val) for significantly upregulated pathways.
Two comparisons were performed:
- Diploid_vs_others: Identifies pathways upregulated in Intestinal Epithelial cells classified as Diploid compared to those with other ploidy states (likely Aneuploid cells, based on obs['ploidy_dec']).
- Tumor_vs_others: Identifies pathways upregulated in Intestinal Epithelial cells from 'tumor' conditions compared to those from 'normal' conditions.
The goal is to understand the functional characteristics and potential mechanisms distinguishing these cellular states within the colon epithelium.
Visual Summary
- GSA_up for Intestinal Epithelial cell: Diploid_vs_others
The bar plot for Diploid vs. others shows a range of significantly upregulated pathways in diploid Intestinal Epithelial cells. The top enriched terms include:
- FoxO signaling pathway: Involved in stress resistance, metabolism, and cell fate.
- Aldosterone-regulated sodium reabsorption: A kidney-specific process, which may indicate a broader metabolic or ion transport theme rather than direct kidney function in the colon.
- Fc gamma R-mediated phagocytosis: Suggests immune-related functions, possibly in clearance or antigen presentation.
- ErbB signaling pathway: Crucial for cell growth, proliferation, and survival.
- Apoptosis: Programmed cell death, vital for tissue homeostasis and tumor suppression.
- Tight junction: Essential for maintaining epithelial barrier integrity.
- Several cancer-related pathways for various cancer types (e.g., Renal cell carcinoma, Non-small cell lung cancer, Pancreatic cancer, Colorectal cancer, Prostate cancer) are also enriched, along with terms like "Central carbon metabolism in cancer" and "Transcriptional misregulation in cancer." This indicates that general cancer-associated processes, or pathways that are often dysregulated in cancer, are active in diploid epithelial cells.
- Metabolic pathways such as Insulin signaling, Nicotinate and nicotinamide metabolism, and mTOR signaling pathway are also prominent.
- GSA_up for Intestinal Epithelial cell: tumor_vs_others
This plot displays pathways significantly upregulated in Intestinal Epithelial cells from tumor samples compared to normal samples. The enrichment signals are generally much stronger (higher -log(p-val) and -log(q-val)) than in the Diploid_vs_others comparison, indicating more pronounced functional shifts. Key enriched categories include:
- Protein synthesis and processing: Highly enriched terms such as Ribosome, Protein processing in endoplasmic reticulum, Proteasome, RNA transport, Spliceosome, and Ribosome biogenesis in eukaryotes. These reflect increased demands for protein production and turnover characteristic of rapidly proliferating cancer cells.
- Metabolic pathways: Oxidative phosphorylation, Thermogenesis, Citrate cycle (TCA cycle), and Pyruvate metabolism are strongly upregulated, pointing to altered energy metabolism, a hallmark of cancer.
- Cell cycle and stress response: Direct mention of Cell cycle, Cellular senescence, Autophagy, Mitophagy, Ferroptosis, and Ubiquitin mediated proteolysis indicate deregulated cell division and increased cellular stress/damage response.
- Infection and immune response: A striking number of pathways related to bacterial and viral infections are enriched, including Salmonella infection, Pathogenic Escherichia coli infection, Epstein-Barr virus infection, Viral carcinogenesis, Vibrio cholerae infection, and Human immunodeficiency virus 1 infection. This suggests an active role of infection-related processes within tumor epithelial cells or their microenvironment.
- Junction integrity: Both Adherens junction and Tight junction appear, suggesting active remodeling or dysregulation of cell-cell contacts.
- Several neurodegenerative disease pathways (e.g., Parkinson's disease, Alzheimer's disease, Huntington disease) are also highly enriched. While not directly related to colon cancer etiology, these terms often reflect underlying cellular dysfunction like protein misfolding, mitochondrial stress, and oxidative damage, which are also prevalent in cancer.
Biological Interpretation
Insights from Diploid Intestinal Epithelial Cells:
The upregulation of pathways like FoxO signaling, ErbB signaling, and Apoptosis in diploid epithelial cells (relative to aneuploid cells) may represent mechanisms crucial for maintaining cellular homeostasis, regulating proliferation, and preventing uncontrolled growth. FoxO signaling, for instance, is known to induce cell cycle arrest and apoptosis, acting as a tumor suppressor [1]. The presence of various cancer-related pathways could imply that even diploid cells within the colon (potentially pre-cancerous or in a non-aggressive tumor context) are already undergoing molecular changes, or that these pathways represent general cellular processes that are often co-opted or dysregulated in different cancers. The enrichment of "Tight junction" pathways underscores the role of diploid cells in maintaining epithelial barrier function, which is often compromised in advanced cancers.
Insights from Tumor Intestinal Epithelial Cells:
The pronounced enrichment of pathways related to protein synthesis, processing, and metabolism in tumor epithelial cells is highly consistent with the 'Warburg effect' and the increased biosynthetic demands of rapidly proliferating cancer cells [2]. Upregulation of the Ribosome, Proteasome, and processes in the ER (protein processing) indicates a high rate of protein turnover and biogenesis necessary for rapid growth. Similarly, altered oxidative phosphorylation and TCA cycle activity highlight metabolic reprogramming that supports tumor survival and proliferation.
The strong signal for infection-related pathways is a critical finding for colorectal cancer (CRC). Chronic inflammation, often triggered by bacterial or viral infections, is a known risk factor for CRC [3, 4]. The presence of pathways related to diverse pathogens within tumor epithelial cells themselves suggests that these cells may be directly responding to microbial stimuli or harboring persistent infections that contribute to tumorigenesis, inflammation, or immune evasion. This warrants further investigation into the specific roles of the microbiome and viral agents in colon cancer progression.
The appearance of neurodegenerative disease pathways should be interpreted cautiously. These pathways often involve mechanisms such as protein misfolding, aggregation, mitochondrial dysfunction, and oxidative stress, which are general cellular stressors and hallmarks of many diseases, including cancer, not just neurological ones [5]. Thus, their enrichment in tumor cells likely reflects heightened cellular stress and dysfunctional protein handling rather than a direct neurological link to colon cancer.
The combined dysregulation of Tight junction and Adherens junction pathways in tumor cells is a key indicator of altered cell-cell adhesion, which is fundamental to epithelial-mesenchymal transition (EMT), invasion, and metastasis in cancer [6].
Clinical or Translational Implications
The GSA results provide valuable insights into the biological underpinnings of colon cancer progression, offering potential avenues for therapeutic intervention and biomarker discovery:
- Metabolic and Protein Synthesis Targeting: The strong upregulation of metabolic pathways (oxidative phosphorylation, TCA cycle) and protein synthesis machinery (ribosomes, proteasome) in tumor epithelial cells highlights these as critical vulnerabilities. Targeting these pathways could inhibit tumor growth and proliferation.
- Infection and Microbiome-Focused Therapies: The significant enrichment of infection-related pathways suggests that modulating the tumor microenvironment, specifically by addressing pathogenic microbes or their inflammatory byproducts, could be a novel therapeutic strategy for CRC. This might involve microbiome-targeted interventions or anti-infective agents.
- Adhesion Junctions as Prognostic Markers/Targets: The dysregulation of tight and adherens junctions in tumor cells could serve as prognostic biomarkers for aggressive disease and potential targets to inhibit metastasis.
- Ploidy-Specific Interventions: Understanding the distinct pathway activities in diploid vs. aneuploid epithelial cells could inform ploidy-specific therapeutic strategies, especially in early-stage disease or for managing heterogeneity within tumors. Pathways like FoxO signaling, if reactivated, could enhance tumor suppression in diploid cancer cells.
References:
[1] GeneCards: FOxO Signaling Pathway. https://www.genecards.org/Pathway/FOXO
[2] PubMed Search: Warburg effect cancer metabolism. https://pubmed.ncbi.nlm.nih.gov/?term=Warburg+effect+cancer+metabolism
[3] PubMed Search: microbiome colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/?term=microbiome+colorectal+cancer
[4] PubMed Search: viral infection colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/?term=viral+infection+colorectal+cancer
[5] PubMed Search: protein misfolding cancer neurodegeneration. https://pubmed.ncbi.nlm.nih.gov/?term=protein+misfolding+cancer+neurodegeneration
[6] PubMed Search: tight junction adherens junction EMT cancer. https://pubmed.ncbi.nlm.nih.gov/?term=tight+junction+adherens+junction+EMT+cancer
22. Major Cell Type GSEA for Colon Tissue: Insights into Tumor Microenvironment Pathways
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot, focusing on key signaling pathways and disease mechanisms across major cell types in human colon tissue under normal and tumor conditions. The analysis compares gene expression profiles to identify pathways that are significantly enriched or depleted in specific cell populations and conditions. The investigated cell types include Intestinal Epithelial cells, T cell CD4+, T cell CD8+, Fibroblast, and B cell. Notably, while Macrophage was requested, it is not displayed in the provided plot. For Intestinal Epithelial cells, comparisons also include ploidy status (Diploid vs. Aneuploid), which is a crucial aspect in cancer biology.
Visual Summary
The dot plot effectively summarizes GSEA results, with each dot representing a specific gene set (pathway) enrichment for a given cell type and comparison.
- X-axis: Represents the different cell type and comparison groups (e.g., "Intestinal Epithelial cell: Diploid_vs_others", "T cell CD4+: tumor_vs_others").
- Y-axis: Lists the enriched gene set pathways.
- Dot Size: Corresponds to the statistical significance (-log(P)), where larger dots indicate more significant enrichment.
- Dot Color: Indicates the Normalized Enrichment Score (NES). Red colors signify pathways enriched in the "test" group (e.g., tumor condition, or diploid cells in the Diploid_vs_others comparison), while blue colors signify pathways enriched in the "reference" group (e.g., normal condition, or aneuploid cells in the Diploid_vs_others comparison). The RdBu_r colormap is used, where red is positive NES and blue is negative NES.
Key Visual Observations:
- Intestinal Epithelial Cells (IECs):
- Diploid_vs_others (Aneuploid): Many cancer-related pathways (e.g., "Colorectal cancer", "Pancreatic cancer", "Prostate cancer", "MAPK signaling pathway", "Ras signaling pathway", "FoxO signaling pathway") show strong negative NES (blue dots, indicating enrichment in aneuploid IECs). This suggests that aneuploid IECs, likely representing transformed or pre-malignant cells, exhibit heightened activity in these oncogenic pathways compared to diploid IECs.
- tumor_vs_others (Normal IECs): Consistently, the same set of cancer-related pathways, along with "Pyrimidine metabolism" (indicating increased proliferation), "Homologous recombination" (DNA repair), and "MicroRNAs in cancer", are highly enriched in tumor IECs (strong red dots) compared to normal IECs. This aligns with the cancerous nature of these cells.
- Immune Cells (T cell CD4+, T cell CD8+, B cell):
- Tumor vs. Normal: In tumor-associated T cells (CD4+ and CD8+) and B cells, there is a strong enrichment (red dots) for various cancer-related pathways ("Colorectal cancer", "Pancreatic cancer", "Prostate cancer") and crucial signaling pathways such as "MAPK signaling pathway", "Ras signaling pathway", "FoxO signaling pathway", "TGF-beta signaling pathway", and "TNF signaling pathway". "Pyrimidine metabolism" and "Homologous recombination" are also enriched, suggesting active proliferation and altered metabolism within these immune cells in the tumor microenvironment.
- Normal vs. Tumor: In contrast, "IL-17 signaling pathway" shows some enrichment (blue dots) in normal T CD4+, T CD8+, and B cells compared to tumor-associated cells, though its enrichment is also observed (red) in tumor-associated T CD4+ cells for other comparisons, suggesting complex regulation.
- Fibroblasts:
- Tumor vs. Normal: Tumor-associated fibroblasts (likely Cancer-Associated Fibroblasts, CAFs) show a striking and highly significant enrichment (large red dots) across almost all interrogated cancer-related and core signaling pathways. This includes "Colorectal cancer", "Pancreatic cancer", "Prostate cancer", "Breast cancer", "MAPK signaling pathway", "Ras signaling pathway", "FoxO signaling pathway", "TGF-beta signaling pathway", and "TNF signaling pathway". "Pyrimidine metabolism" and "Homologous recombination" are also strongly enriched, indicating their active, pro-tumorigenic role. "Vascular smooth muscle contraction" is also enriched, consistent with stromal remodeling.
Biological Interpretation
The GSEA results provide a comprehensive view of pathway activity shifts in different cell types within the colon tumor microenvironment.
- Intestinal Epithelial Cells as Tumor Origin: The profound enrichment of oncogenic pathways (MAPK, Ras, FoxO) and cancer-specific pathways in both aneuploid and tumor-condition IECs confirms their direct involvement in tumorigenesis and rapid proliferation ("Pyrimidine metabolism"). The observation that aneuploid IECs already show enrichment in these cancer pathways compared to diploid IECs suggests that chromosomal instability and aneuploidy might precede or coincide with the activation of these pro-tumorigenic pathways. [PubMed search: aneuploidy and cancer pathways colon]
- Immune Cell Reprogramming in the TME: The robust activation of key signaling pathways (MAPK, Ras, FoxO, TGF-beta, TNF) in tumor-infiltrating T cells (CD4+, CD8+) and B cells highlights their significant reprogramming within the tumor microenvironment (TME).
- MAPK and Ras signaling are critical for T cell activation, proliferation, and differentiation, but sustained activation in the TME can lead to exhaustion or a pro-tumorigenic phenotype. [GeneCards: MAPK pathway]
- FoxO signaling plays complex roles in T cell survival, quiescence, and differentiation, and its deregulation can contribute to immune evasion. [UniProt: FOXO proteins]
- TGF-beta and TNF signaling are central to immune suppression and inflammation, respectively, profoundly shaping the anti-tumor immune response. TGF-beta often promotes an immunosuppressive environment, leading to T cell anergy and fibroblast activation. TNF can have dual roles, being pro-inflammatory but also contributing to chronic inflammation that can support tumor growth. [PubMed search: TGFB TME colon cancer]
- Cancer-Associated Fibroblasts (CAFs) as Key Orchestrators: The extensive enrichment of oncogenic, proliferative, and immune-modulatory pathways in tumor-associated fibroblasts underscores their critical role as Cancer-Associated Fibroblasts (CAFs). CAFs are known to secrete growth factors, cytokines (e.g., via TGF-beta and TNF signaling), and remodel the extracellular matrix ("Vascular smooth muscle contraction"), fostering tumor growth, invasion, and immunosuppression. Their active involvement in DNA repair ("Homologous recombination") and rapid division ("Pyrimidine metabolism") further emphasizes their dynamic and supportive role in the TME. [PubMed search: cancer associated fibroblasts colon cancer]
- IL-17 Signaling: The differential enrichment of "IL-17 signaling pathway" suggests a nuanced role. Its enrichment in normal immune cells might reflect homeostatic inflammatory responses, while its presence in tumor-associated cells could indicate chronic inflammation that can either promote or inhibit tumor progression depending on the context and cellular source.
Clinical or Translational Implications
- Targeting Core Pathways: The consistent enrichment of MAPK, Ras, FoxO, TGF-beta, and TNF signaling pathways across multiple tumor-associated cell types (IECs, T cells, B cells, Fibroblasts) suggests these pathways are central to colon cancer progression. Targeting these pathways could offer broad therapeutic benefits, potentially by inhibiting tumor growth directly (in IECs) and by modulating the pro-tumorigenic functions of stromal and immune cells in the TME.
- Cell-Type-Specific Interventions: Understanding which cell types activate specific pathways can guide the development of more precise, cell-type-specific therapies. For example, simultaneously targeting Ras/MAPK in tumor cells and CAFs could be more effective than targeting only one cell type.
- Prognostic and Predictive Biomarkers: The distinct pathway signatures, particularly the enrichment of cancer pathways in aneuploid IECs, could serve as prognostic indicators for disease aggressiveness or as predictive biomarkers for response to specific therapies.
- Immunotherapy Strategies: The altered signaling in tumor-infiltrating T and B cells, particularly involving TGF-beta and TNF, highlights potential avenues for improving immunotherapy efficacy by counteracting immunosuppressive mechanisms or enhancing anti-tumor immune responses within the TME.
- Macrophage Data Gap: The absence of Macrophage data, despite its request, is a limitation. Given Macrophages (especially M2-like) are significant contributors to the TME in colon cancer, their pathway enrichment analysis would provide further crucial insights into the immune landscape and potential therapeutic targets.
23. Discussion
The comprehensive single-cell analysis of human colon tissue provides a granular understanding of the cellular and molecular adaptations within the tumor microenvironment (TME). The identification of Intestinal Epithelial cells as the tumor origin is strongly supported by their aneuploid status, recurrent genomic amplifications (notably affecting MYC on chromosome 8 and genes on 19q), and widespread activation of cell cycle and oncogenic pathways (MAPK, Ras, FoxO, Pyrimidine metabolism). This malignant transformation is accompanied by a profound remodeling of the surrounding stromal and immune compartments.
A striking observation is the significant increase in cancer-associated fibroblasts (CAFs) in tumor samples, which exhibit a highly activated, pro-tumorigenic surfaceome profile (e.g., MMP14, ANTXR1, ITGAV) and extensive enrichment of cancer-related signaling pathways (MAPK, Ras, TGF-beta, TNF). CAFs emerge as central orchestrators of tumor progression, actively engaging in ECM remodeling and creating a supportive niche for tumor cells.
The immune landscape within the TME is characterized by a notable shift towards immunosuppression and chronic inflammation. Specifically, there is a highly significant expansion of regulatory T cells (Tregs), Th17, and Th22 populations. Tregs actively suppress anti-tumor immunity, while Th17 and Th22 cells often contribute to pro-tumorigenic inflammation and tissue repair in the context of cancer. This indicates a TME that actively dampens effective anti-tumor immune responses. Macrophage populations also undergo re-polarization, with an increase in pro-tumorigenic M2D and M2B subsets, despite a sustained M1-like presence. This complex macrophage phenotype suggests a dual role of immune activation and suppression, where M1 may attempt to combat the tumor but is likely counteracted by M2-mediated immunosuppression.
Cell-cell interaction analysis reveals a profound rewiring of intercellular communication in the tumor. The absence of beneficial IFN-γ signaling and the emergence of critical immune checkpoints such as NECTIN2-TIGIT, BTLA-TNFRSF14, and SIRPG-CD47 in the tumor context underscore active immune evasion strategies employed by tumor cells and their associated stromal/immune components. Furthermore, epithelial-immune interactions involving CEACAM5 and CD8A suggest direct impact on T cell function.
Perhaps one of the more unexpected and notable findings is the significant enrichment of numerous infection-related pathways (e.g., Salmonella, pathogenic E. coli, Epstein-Barr virus, HIV) in tumor Intestinal Epithelial cells identified through Gene Ontology analysis. While chronic inflammation is a known risk factor for colorectal cancer, the direct implication of diverse pathogen-related pathways within the tumor epithelial cells themselves suggests a deeper, potentially causative or exacerbating role of microbial stimuli in driving or maintaining the malignant phenotype. This finding warrants further investigation into the direct interaction between pathogens, host immune responses, and epithelial cell transformation in colon cancer. The co-enrichment of neurodegenerative disease pathways in tumor cells, though seemingly unrelated, likely reflects general cellular stressors such as protein misfolding and mitochondrial dysfunction prevalent in aggressive cancers. Overall, these analyses provide a high-resolution map of colon cancer, highlighting genomic instability, metabolic reprogramming, and a highly sophisticated immune evasion landscape.
Hypotheses:
- The recurrent amplifications, particularly involving the MYC oncogene on chromosome 8 and regions on 19q, drive the initial malignant transformation or enhance the aggressive phenotype of colon cancer epithelial cells, even in the context of overall diploidy.
- The dominant M1 macrophage population in colon tumors, despite the presence of pro-tumorigenic M2 subsets, represents a sustained host anti-tumor immune response that is ultimately overcome or modulated by other immunosuppressive mechanisms, such as increased Tregs and immune checkpoint activation.
- The observed enrichment of infection-related pathways within tumor Intestinal Epithelial cells suggests that specific microbial interactions or chronic infections contribute directly to colon cancer progression, potentially by promoting inflammation, genomic instability, or epithelial-mesenchymal transition.
- Cancer-associated fibroblasts (CAFs) actively reprogram the tumor microenvironment through diverse surface interactions and cytokine production (e.g., via TGF-beta and TNF signaling), fostering immune evasion and tumor metastasis, with specific CAF subtypes exhibiting distinct pro-tumorigenic functions.
- The loss of IFN-γ signaling and upregulation of inhibitory immune checkpoints (e.g., TIGIT, BTLA, CD47) in the tumor microenvironment are central mechanisms through which colon cancer cells and associated immune cells suppress effective anti-tumor immunity.
Potential therapeutic targets:
- MYC oncogene: MYC is a potent proto-oncogene frequently amplified and overexpressed in colorectal cancer, driving cell proliferation, growth, and survival. Its amplification was recurrently observed in tumor-origin Intestinal Epithelial cells. Evidence: Recurrent amplifications on chromosome 8q21.3:8q24.21, encompassing the MYC locus, were observed in tumor samples (Section 4). MYC upregulation was also seen in cell cycle analysis (Section 20) and enriched pathways (Section 22). Validation: Investigate the efficacy of MYC inhibitors or strategies to destabilize MYC protein in colon cancer cell lines and organoids with MYC amplification, followed by in vivo efficacy studies.
- CEACAM5: CEACAM5 is a known tumor marker frequently overexpressed in colorectal cancer, implicated in cell adhesion, proliferation, and immune evasion, making it an ideal surface-accessible target. Evidence: Highly and specifically upregulated on tumor-origin Intestinal Epithelial cells (Section 16). Involved in tumor-associated cell-cell interactions (CEACAM5-CD8A, Section 13, 15). Validation: Evaluate the anti-tumor efficacy of CEACAM5-targeting antibody-drug conjugates (ADCs) or CAR T-cells in colon cancer models that express high levels of CEACAM5.
- TIGIT: TIGIT is an immune checkpoint receptor that suppresses anti-tumor immunity when engaged by its ligands (e.g., NECTIN2) on tumor cells or other TME components. Blocking TIGIT can reactivate exhausted T cells. Evidence: NECTIN2-TIGIT interaction was highly prominent and significantly enriched in tumor samples, particularly between diploid Intestinal Epithelial cells and CD4+ T cells (Section 15). Validation: Test the therapeutic potential of anti-TIGIT antibodies, alone or in combination with other immune checkpoint inhibitors (e.g., anti-PD-1), in colon cancer patient-derived xenograft (PDX) models or syngeneic models.
- CTLA4: CTLA4 is a critical inhibitory receptor on T cells, dampening T cell responses and promoting immune evasion. Its upregulation in tumor-infiltrating CD4+ T cells suggests a mechanism of immune suppression. Evidence: Significantly upregulated as a tumor-specific surface marker in CD4+ T cells in tumor conditions (Section 19). Validation: Assess the impact of CTLA4 blockade (e.g., with ipilimumab or novel antibodies) on CD4+ T cell activation, proliferation, and anti-tumor efficacy in colon cancer models.
- MMP14 / ANTXR1: MMP14 is a key enzyme for extracellular matrix degradation and tumor invasion. ANTXR1 is linked to angiogenesis and tumor growth. Both are highly expressed by cancer-associated fibroblasts (CAFs), which are crucial for tumor progression. Evidence: MMP14 and ANTXR1 are significantly upregulated as tumor-specific surface markers in fibroblasts from tumor samples (Section 18). Validation: Develop and test inhibitors or antibodies targeting MMP14 or ANTXR1 to modulate CAF function, reduce ECM remodeling, and inhibit tumor invasion/angiogenesis in colon cancer models.
- ENTPD1 (CD39): CD39 is an ectonucleotidase involved in adenosine production, a potent immunosuppressive molecule in the tumor microenvironment, and is expressed on immunosuppressive T cells. Evidence: Upregulated as a tumor-specific surface marker in CD4+ T cells in tumor conditions (Section 19). Validation: Evaluate CD39 inhibitors to counteract adenosine-mediated immunosuppression and enhance anti-tumor immunity in colon cancer models.
Follow-up validation ideas:
- Confirm MYC amplification and 19q gains in tumor epithelial cells using targeted qPCR or fluorescence in situ hybridization (FISH) on a larger cohort of colorectal cancer samples, correlating findings with clinical outcomes.
- Validate the increased proportions of Tregs (FOXP3, CTLA4), Th17 (RORC, IL-17), Th22 (IL-22), M2D/M2B macrophages (CD163, CD206, CD39), and M1 macrophages (CD80, CD86, IFNGR1) in tumor tissue via multiplex immunohistochemistry or flow cytometry on fresh tumor biopsies.
- Functionally validate critical immune checkpoint interactions (e.g., NECTIN2-TIGIT, SIRPG-CD47) and tumor-promoting adhesion molecules (e.g., CEACAM5-CD8A) using CRISPR-mediated gene editing in colon cancer cell lines and co-culture systems with immune cells, followed by in vivo tumor growth and immune infiltration studies.
- Investigate the specific microbial species associated with colon tumors showing high enrichment of infection-related pathways. Perform in vitro co-culture experiments with candidate pathogens and normal/transformed colon epithelial cells to assess impacts on proliferation, inflammation, and immune evasion.
- Use spatial transcriptomics or proteomics to map the distribution and functional states of distinct CAF subsets (identified by markers like MMP14, ANTXR1, CDH11) within the colon tumor microenvironment and correlate their proximity to immune cells and tumor cells with tumor progression markers.
- Validate key differentially expressed surface markers (e.g., MUC4, CEACAM5, CD44 on tumor epithelial cells; CTLA4, CD39 on CD4+ T cells; MMP14, ANTXR1 on fibroblasts) using larger, independent cohorts of colon cancer patients via bulk RNA-seq, proteomics, or advanced multiplex imaging to assess prognostic or predictive value.
- Employ specific inhibitors for highly enriched oncogenic pathways (e.g., MAPK, Ras, TGF-beta) and cell cycle regulators (e.g., CDK4/6, HDACs) in patient-derived organoids or xenograft models to assess their impact on tumor growth and TME composition.
Limitations:
The interpretations presented herein are derived from a single-cell RNA-sequencing dataset and computational analyses. While robust, these findings are correlative and require further experimental validation to establish causality. The inferred CNVs and ploidy status are computational estimates and may not capture all genomic alterations. The functional states of immune cells are inferred from marker expression and pathway enrichment and would benefit from direct functional assays. The observed inter-sample heterogeneity underscores the complexity of colon cancer and suggests that findings from this cohort may not be universally applicable to all colorectal cancer subtypes or stages. The absence of certain cell types (e.g., Macrophages in GSEA) or specific ligand-receptor interactions from visualization does not necessarily imply their biological irrelevance, but rather reflects the applied filtering thresholds and the scope of the presented analyses.
24. Query List
- Show UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save them.
- Show expression of CD3D CD4 CD8A CD79A MS4A1 MZB1 CD14 LYZ FBLN1 NOTCH3 EPCAM MUC1 CD34 genes on UMAP along with minor cell type annotation. Set ncols=4 and save.
- Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
- Select tumor-origin cells (Intestinal Epithelial cell) and unassigned cells, group by sample, show a CNV heatmap, and include a summary of significantly amplified regions. Save the results.
- Show CNV patterns as a UMAP. Include major cell type, minor cell type, ploidy results, condition, and sample in 2 columns, and save it.
- Show a population bar plot of minor cell types and save it.
- Show a subset population barplot for T cells and save it.
- Show a subset population barplot for macrophages and save it.
- For T cell subset populations, show a boxplot for statistically significant differences between conditions and save it. Determine ncols appropriately based on the total number of panels.
- For macrophage subset populations, show a boxplot for statistically significant differences between conditions and save it. Determine ncols appropriately based on the total number of panels.
- Select tumor-origin cells (Intestinal Epithelial cell) and unassigned cells, show a bar plot of their ploidy population, and save it.
- Show cell-cell interaction patterns including tumor-origin cells (Intestinal Epithelial cell), fibroblasts, macrophages, and T cells by condition and save them. Select up to 80 cell-cell interactions per condition.
- Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
- Select only immune checkpoint and cell cycle pathway-related genes, show cell-cell interactions for these genes, and save them.
- Find statistically significant differences in cell-cell interactions between conditions for major immune and stromal cells, show them as a dot plot, and save it. Set max_n_items_per_group = 25.
- Show the condition-specific markers for tumor-origin cells (Intestinal Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
- Extract condition-specific markers for macrophages, show them as a dot plot, and save it. Show only surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for fibroblasts, show them as a dot plot, and save it. Show only surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for CD4 T cells, show them as a dot plot, and save it. Show only surfaceome markers, up to 50 per condition.
- For major disease-related cell types (Intestinal Epithelial cell, Fibroblast, Macrophage, T cell), find statistically significant differences in expression between conditions for cell cycle pathway-related genes, show them as a box plot, and save it. Set max_n_items_to_plot = 24, and set ncols appropriately so that the width-to-height ratio of the overall panel is approximately 2x3.
- Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
- Show a dot plot of Gene set enrichment analysis (GSEA) results for major cell types (Intestinal Epithelial cell, T cell CD4+, T cell CD8+, Fibroblast, Macrophage, B cell) and save it. Set color map to RdBu_r and n_pws_to_show = 80.





















